<SEC-DOCUMENT>0001193125-24-191518.txt : 20240801
<SEC-HEADER>0001193125-24-191518.hdr.sgml : 20240801
<ACCEPTANCE-DATETIME>20240801161131
ACCESSION NUMBER:		0001193125-24-191518
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240801
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240801
DATE AS OF CHANGE:		20240801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aldeyra Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001341235
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36332
		FILM NUMBER:		241166774

	BUSINESS ADDRESS:	
		STREET 1:		131 HARTWELL AVENUE
		STREET 2:		SUITE 320
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		781-761-4904

	MAIL ADDRESS:	
		STREET 1:		131 HARTWELL AVENUE
		STREET 2:		SUITE 320
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aldexa Therapeutics, Inc.
		DATE OF NAME CHANGE:	20130102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Neuron Systems Inc
		DATE OF NAME CHANGE:	20051012
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d814773d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:aldx="http://aldeyra.com/20240801" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-259">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-08-01_to_2024-08-01">0001341235</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="aldx-20240801.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-08-01_to_2024-08-01"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-08-01</xbrli:startDate> <xbrli:endDate>2024-08-01</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-270">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-08-01_to_2024-08-01" format="ixt:datemonthdayyearen" id="ixv-271">August&#160;1, 2024</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-272">ALDEYRA THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-08-01_to_2024-08-01" format="ixt-sec:stateprovnameen" id="ixv-273">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-274">001-36332</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-275">20-1968197</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File No.)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-276">131 Hartwell Avenue</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-277">Suite 320</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-278">Lexington</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-279">MA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-280">02421</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices and zip code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-281">(781)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-282">761-4904</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-08-01_to_2024-08-01" format="ixt-sec:boolballotbox" id="ixv-283">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-08-01_to_2024-08-01" format="ixt-sec:boolballotbox" id="ixv-284">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-08-01_to_2024-08-01" format="ixt-sec:boolballotbox" id="ixv-285">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-08-01_to_2024-08-01" format="ixt-sec:boolballotbox" id="ixv-286">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-287">Common Stock, $0.001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-288">ALDX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-08-01_to_2024-08-01" format="ixt-sec:exchnameen" id="ixv-289">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-08-01_to_2024-08-01" format="ixt-sec:boolballotbox" id="ixv-290">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Open Market Sale Agreement</span><sup style="font-size:75%; vertical-align:top">SM</sup> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously reported, on March&#160;11, 2021, Aldeyra Therapeutics, Inc. (the &#8220;Company&#8221;) entered into a sale agreement with Jefferies LLC (&#8220;Agent&#8221;) to sell shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), from time to time through the Agent, acting as sales agent, having a maximum aggregate offering price of $100,000,000 (the &#8220;Prior Sales Agreement&#8221;). The issuances and sales under the Prior Sales Agreement, if any, were to be made pursuant to the Company&#8217;s registration statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-254175)</span> filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March&#160;11, 2021 (the &#8220;Prior Registration Statement&#8221;). The Prior Registration Statement expired on April&#160;15, 2024, and no sales had been made pursuant to the Prior Sales Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;7, 2024, the Company filed a registration statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-277753)</span> (the &#8220;Registration Statement&#8221;), which was declared effective by the SEC on April&#160;24, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2024, the Company entered into a new Open Market Sale Agreement<sup style="font-size:75%; vertical-align:top">SM</sup> (the &#8220;Sales Agreement&#8221;), thereby terminating the Prior Sales Agreement, to sell shares of Common Stock from time to time through Agent, acting as sales agent. Pursuant to the prospectus supplement dated August&#160;1, 2024 (the &#8220;Prospectus Supplement&#8221;) filed by the Company with the SEC, which supplements the base prospectus included in the Registration Statement, the Company will be able to offer and sell up to $75,000,000 of its shares of Common Stock pursuant to the Sales Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agent may sell the common stock by methods deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will designate the maximum amount of common stock to be sold through the Agent in any placement under the Sales Agreement. Subject to the terms and conditions of the Sales Agreement, the Agent has agreed to use its commercially reasonable efforts to sell on the Company&#8217;s behalf all of the shares of Common Stock requested to be sold by the Company. The Company may instruct the Agent not to sell common stock if the sales cannot be effected at or above a price designated by the Company in a placement notice. The Company or the Agent may suspend the offering of Common Stock pursuant to the Sales Agreement upon proper notice to the other party. The Company and the Agent each have the right, by giving written notice as specified in the Sales Agreement, to terminate the Sales Agreement in each party&#8217;s sole discretion at any time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sales Agreement provides that the Agent will be entitled to aggregate compensation for its services of up to 3.0% of the gross sales price per share of all shares sold through the Agent under the Sales Agreement. The Company has no obligation to sell any shares under the Sales Agreement. The Company has agreed in the Sales Agreement to provide indemnification and contribution to the Agent against certain liabilities, including liabilities under the Securities Act. In addition, the Company has agreed to reimburse certain legal expenses incurred by the Agent in connection with execution of the Sales Agreement in an amount up to $75,000, in addition to certain ongoing legal expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> (the &#8220;Current Report&#8221;) and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The legal opinion of Gunderson Dettmer Stough Villeneuve Franklin&#160;&amp; Hachigian, LLP relating to the shares of Common Stock being sold pursuant to the Sales Agreement is filed as Exhibit 5.1 to this Current Report. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d814773dex11.htm">Open Market Sale Agreement<sup style="font-size:75%; vertical-align:top">SM</sup> by and between the Company and Jefferies LLC, dated August&#160;1, 2024. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d814773dex51.htm">Opinion of Gunderson Dettmer Stough Villeneuve Franklin&#160;&amp; Hachigian, LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d814773dex51.htm">Consent of Gunderson Dettmer Stough Villeneuve Franklin&#160;&amp; Hachigian, LLP (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:13%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:86%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">ALDEYRA THERAPEUTICS, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Todd C. Brady</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Todd C. Brady, M.D., Ph.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Chief Executive Officer</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: August&#160;1, 2024 </p>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d814773dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OPEN MARKET SALE AGREEMENT</U><SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">August&nbsp;1, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aldeyra Therapeutics,
Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the &#147;<B>Agent</B>&#148;),
shares of the Company&#146;s common stock, par value $0.001 per share (the &#147;<B>Common Shares</B>&#148;), having an aggregate offering price of up to $75,000,000 on the terms set forth in this agreement (this &#147;<B>Agreement</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1. DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<U>Certain Definitions</U>. For purposes of this Agreement, capitalized terms used herein and not otherwise defined shall have the following respective meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; of a Person means another Person that directly or indirectly, through one or more intermediaries, controls, is
controlled by, or is under common control with, such first- mentioned Person. The term &#147;control&#148; (including the terms &#147;controlling,&#148; &#147;controlled by&#148; and &#147;under common control with&#148;) means the possession,
direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agency Period</B>&#148; means the period commencing on the date of this Agreement and expiring on the earliest to occur of
(x)&nbsp;the date on which the Agent shall have placed the Maximum Program Amount pursuant to this Agreement and (y)&nbsp;the date this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Commission</B>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Floor Price</B>&#148; means the minimum price set by the Company in the Issuance Notice below which the
Agent shall not sell Shares during the applicable period set forth in the Issuance Notice, which may be adjusted by the Company at any time during the period set forth in the Issuance Notice by delivering written notice of such change to the Agent
and which in no event shall be less than $1.00 without the prior written consent of the Agent, which may be withheld in the Agent&#146;s sole discretion. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">SM</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Open Market Sale Agreement&#148; is a service mark of Jefferies LLC </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Amount</B>&#148; means the aggregate Sales Price of the Shares to be sold
by the Agent pursuant to any Issuance Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Notice</B>&#148; means a written notice delivered to the Agent by the
Company in accordance with this Agreement in the form attached hereto as <U>Exhibit A</U> that is executed by its Chief Executive Officer, President or Chief Financial Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Notice Date</B>&#148; means any Trading Day during the Agency Period that an Issuance Notice is delivered pursuant to
<U>Section</U><U></U><U>&nbsp;3(b)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Price</B>&#148; means the Sales Price less the Selling Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Maximum Program Amount</B>&#148; means Common Shares with an aggregate Sales Price of the lesser of (a)&nbsp;the number or dollar
amount of Common Shares registered under the effective Registration Statement (defined below) pursuant to which the offering is being made, (b)&nbsp;the number of authorized but unissued Common Shares (less Common Shares issuable upon exercise,
conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#146;s authorized capital stock), (c) the number or dollar amount of Common Shares permitted to be sold under Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (including General Instruction I.B.6 thereof, if applicable), or (d)&nbsp;the number or dollar amount of Common Shares for which the Company has filed a Prospectus (defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means an individual or a corporation, partnership, limited liability company, trust, incorporated or unincorporated
association, joint venture, joint stock company, governmental authority or other entity of any kind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Principal Market</B>&#148;
means The Nasdaq Capital Market or such other national securities exchange on which the Common Shares, including any Shares, are then listed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sales Price</B>&#148; means the actual sale execution price of each Share placed by the Agent pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Selling Commission</B>&#148; means up to three percent (3.0%) of the gross proceeds of Shares sold pursuant to this
Agreement, or as otherwise agreed between the Company and the Agent with respect to any Shares sold pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Settlement Date</B>&#148; means the first business day following each Trading Day during the period set forth in the Issuance Notice
on which Shares are sold pursuant to this Agreement, when the Company shall deliver to the Agent the amount of Shares sold on such Trading Day and the Agent shall deliver to the Company the Issuance Price received on such sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Shares</B>&#148; means the Company&#146;s Common Shares issued or issuable pursuant
to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trading Day</B>&#148; means any day on which the Principal Market is open for trading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company represents and warrants to, and agrees with, the Agent that as of (1)&nbsp;the date of this Agreement, (2)&nbsp;each Issuance
Notice Date, (3)&nbsp;each Settlement Date, (4)&nbsp;each Triggering Event Date and (5)&nbsp;as of each Time of Sale (each of the times referenced above is referred to herein as a &#147;<B>Representation Date</B>&#148;), except as may be disclosed
in the Prospectus (including any documents incorporated by reference therein and any supplements thereto) on or before a Representation Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Registration Statement</U>. The Company has prepared and filed with the Commission a shelf registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (File No. <FONT STYLE="white-space:nowrap">333-277753)&nbsp;that</FONT> contains a base prospectus (the &#147;<B>Base Prospectus</B>&#148;). Such registration statement registers the issuance and sale
by the Company of the Shares under the Securities Act. The Company may file one or more additional registration statements from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable, with
respect to the Shares. Except where the context otherwise requires, such registration statement(s), including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, including all financial statements, exhibits
and schedules thereto and all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act as from time to time amended or supplemented, is
herein referred to as the &#147;<B>Registration Statement</B>,&#148; and the prospectus constituting a part of such registration statement(s), together with any prospectus supplement filed with the Commission pursuant to Rule 424(b) under the
Securities Act relating to a particular issuance of the Shares, including all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act,
in each case, as from time to time amended or supplemented, is referred to herein as the &#147;<B>Prospectus</B>,&#148; except that if any revised prospectus is provided to the Agent by the Company for use in connection with the offering of the
Shares that is not required to be filed by the Company pursuant to Rule 424(b) under the Securities Act, the term &#147;<B>Prospectus</B>&#148; shall refer to such revised prospectus from and after the time it is first provided to the Agent for such
use. The Registration Statement at the time it originally became effective is herein called the &#147;<B>Original Registration Statement</B>.&#148; As used in this Agreement, the terms &#147;amendment&#148; or &#147;supplement&#148; when applied to
the Registration Statement or the Prospectus shall be deemed to include the filing by the Company with the Commission of any document under the Exchange Act after the date hereof that is or is deemed to be incorporated therein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to financial statements and schedules and other information which is &#147;contained,&#148;
&#147;included&#148; or &#147;stated&#148; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information which is or is
deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date; and all references in this Agreement to
amendments or supplements to the Registration Statement or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus shall be deemed to mean and include, without limitation, the filing of any document under the Exchange Act which is or is deemed to be incorporated by reference in or otherwise deemed
under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date. The Company&#146;s obligations under this Agreement to furnish, provide, deliver or make available
(and all other references of like import) copies of any report or statement shall be deemed satisfied if the same is filed with the Commission through EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time the Original Registration Statement was declared effective and at the time the Company&#146;s most recent annual report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> was filed with the Commission, if later, the Company met the then-applicable requirements for use of <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> under the Securities Act. During the Agency
Period, each time the Company files an annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> the Company will meet the then-applicable requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Compliance with Registration Requirements</U>. The Original Registration Statement and any Rule&nbsp;462(b) Registration Statement
have been or will be declared effective by the Commission under the Securities Act. The Company has complied, or will comply with, the Commission&#146;s satisfaction with all requests of the Commission for additional or supplemental information, if
any. No stop order suspending the effectiveness of the Registration Statement or any Rule&nbsp;462(b) Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company,
are contemplated or threatened by the Commission.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus when filed
complied or will comply in all material respects with the Securities Act and, if filed with the Commission through its Electronic Data Gathering, Analysis and Retrieval system (&#147;<B>EDGAR</B>&#148;) (except as may be permitted by <FONT
STYLE="white-space:nowrap">Regulation&nbsp;S-T</FONT> under the Securities Act), was identical to the copy thereof delivered to the Agent for use in connection with the issuance and sale of the Shares. Each of the Registration Statement, any
Rule&nbsp;462(b) Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective and at each Representation Date, complied and will comply in all material respects with the Securities Act and did not and
will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the date of this Agreement, the Prospectus and any Free Writing
Prospectus (as defined below) considered together (collectively, the &#147;<B>Time of Sale Information</B>&#148;) did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading. The Prospectus, as amended or supplemented, as of its date and at each Representation Date, did not and will not contain any untrue statement of a material fact or omit to
state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not
apply to statements in or omissions from the Registration Statement, any Rule&nbsp;462(b) Registration Statement, or any post-effective amendment thereto, or the Prospectus, or any amendments or supplements thereto, made in reliance upon and in
conformity with information relating to the Agent furnished to the Company in writing by the Agent expressly for use therein, it being understood and agreed that the only such information furnished by the Agent to the Company consists of the
information described in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;6</U> below. There are no contracts or other documents required to be described in the Prospectus or to be filed as exhibits to the Registration Statement which have
not been described or filed as required. The Registration Statement and the offer and sale of the Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Ineligible Issuer Status</U>. The Company is not an &#147;ineligible issuer&#148; in connection with the offering of the Shares
pursuant to Rules 164, 405 and 433 under the Securities Act. Any Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the
requirements of the Securities Act. Each Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company
complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act including timely filing with the Commission or retention where required and legending, and each such Free Writing Prospectus, as of its issue
date and at all subsequent times through the completion of the issuance and sale of the Shares did not, does not and will not include any information that conflicted, conflicts with or will conflict with the information contained in the Registration
Statement or the Prospectus, including any document incorporated by reference therein. Except for the Free Writing Prospectuses, if any, and electronic road shows, if any, furnished to the Agent before first use, the Company has not prepared, used
or referred to, and will not, without the Agent&#146;s prior consent, prepare, use or refer to, any Free Writing Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
<U>Incorporated Documents</U>. The documents incorporated or deemed to be incorporated by reference in the Registration Statement and the Prospectus, at the time they were filed with the Commission, complied in all material respects with the
requirements of the Exchange Act, as applicable, and, when read together with the other information in the Prospectus, do not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exchange Act
Compliance</U>. The documents incorporated or deemed to be incorporated by reference in the Prospectus, at the time they were or hereafter are filed with the Commission, and any Free Writing Prospectus or amendment or supplement thereto complied and
will comply in all material respects with the requirements of the Exchange Act, and, when read together with the other information in the Prospectus, at the time the Registration Statement and any amendments thereto become effective and as of each
Representation Date, as the case may be, will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the fact required to be stated therein or necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Disclosure of Agreements</U>.
The agreements and documents described in the Registration Statement and the Prospectus conform in all material respects to the descriptions thereof contained therein and there are no agreements or other documents required by the Securities Act to
be described in the Registration Statement and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement, that have not been so described or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
filed. Each agreement or other instrument (however characterized or described) to which the Company is a party or by which it is or may be bound or affected and that is referred to in the
Registration Statement and the Prospectus, has been duly authorized and validly executed by the Company, is in full force and effect in all material respects and is enforceable against the Company and, to the Company&#146;s knowledge, the other
parties thereto, in accordance with its terms, except (x)&nbsp;as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&#146; rights generally, (y)&nbsp;as enforceability of any
indemnification or contribution provision may be limited under the federal and state securities laws, and (z)&nbsp;that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses
and to the discretion of the court before which any proceeding therefor may be brought. None of such agreements or instruments has been assigned by the Company, and neither the Company nor, to the Company&#146;s knowledge, any other party is in
default thereunder and, to the Company&#146;s knowledge, no event has occurred that, with the lapse of time or the giving of notice, or both, would constitute a default thereunder except for any such defaults that would not have or reasonably be
expected to result in a Material Adverse Change (as defined below). To the Company&#146;s knowledge, performance by the Company of the material provisions of such agreements or instruments will not result in a material violation of any existing
applicable law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or businesses (each, a &#147;<B>Governmental Entity</B>&#148;),
including, without limitation, those relating to environmental laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Prior Securities Transactions</U>. Since
December&nbsp;31, 2020, no securities of the Company have been sold by the Company or by or on behalf of, or for the benefit of, any person or persons controlling, controlled by or under common control with the Company, except as disclosed in the
Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Regulations</U>. The disclosures in the Registration Statement and the Prospectus
concerning the effects of federal, state, local and all foreign regulation on the offering and the Company&#146;s business as currently contemplated are correct in all material respects and no other such regulations are required to be disclosed in
the Registration Statement and the Prospectus which are not so disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>No Material Adverse Change</U>. Since the respective
dates as of which information is given in the Registration Statement and the Prospectus, except as otherwise specifically stated therein: (i)&nbsp;there has been no material adverse change in the financial position or results of operations of the
Company and its subsidiaries, taken as a whole, nor any change or development that, singularly or in the aggregate, would reasonably be expected to result in a material adverse change, in or affecting the condition (financial or otherwise), results
of operations, business, assets or prospects of the Company and its subsidiaries, taken as a whole (a &#147;<B>Material Adverse Change</B>&#148;); (ii) there have been no material transactions entered into by the Company, other than as contemplated
pursuant to this Agreement; and (iii)&nbsp;except, as otherwise disclosed to the Agent, no officer or director of the Company or any of its subsidiaries has resigned from any position with the Company or such subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Recent Securities Transactions, etc</U>. Subsequent to the respective dates as of
which information is given in the Registration Statement and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the Registration Statement and the Prospectus, the Company has not: (i)&nbsp;issued any
securities (other than equity compensation to service providers in the normal course of business) or incurred any liability or obligation, direct or contingent, for borrowed money; or (ii)&nbsp;declared or paid any dividend or made any other
distribution on or in respect to its capital stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Organization and Good Standing</U>. Each of the Company and its subsidiaries
has been duly organized and is validly existing as a corporation or other business entity and is in good standing under the laws of the jurisdiction in which it is chartered or organized as of the date hereof (to the extent such concept is
applicable in such jurisdictions), and is duly qualified to do business and is in good standing in each other jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification, except where the failure
to so qualify, singularly or in the aggregate, would not have or reasonably be expected to result in a Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)
<U>Outstanding Securities</U>. All issued and outstanding securities of the Company and each of its subsidiaries issued prior to the transactions contemplated by this Agreement have been duly authorized and validly issued and are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable;</FONT> the holders thereof have no rights of rescission with respect thereto, and are not subject to personal liability by reason of being such holders; and none of such securities were issued in violation
of the preemptive rights of any holders of any security of the Company or any of its subsidiaries, as applicable, or similar contractual rights granted by the Company or any of its subsidiaries, as applicable. The authorized Common Shares conform in
all material respects to all statements relating thereto contained in the Registration Statement and the Prospectus. The offers and sales of the outstanding Common Shares were at all relevant times either registered under the Securities Act and the
applicable state securities or &#147;blue sky&#148; laws or, based in part on the representations and warranties of the purchasers of such shares, exempt from such registration requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>The Shares</U>. The Shares have been duly authorized for issuance and sale and, when issued and paid for, will be validly issued, fully
paid and <FONT STYLE="white-space:nowrap">non-assessable;</FONT> the holders thereof are not and will not be subject to personal liability by reason of being such holders; the Shares are not and will not be subject to the preemptive rights or rights
of first refusal of any holders of any security of the Company or similar contractual rights granted by the Company; and all corporate action required to be taken for the authorization, issuance and sale of the Shares have been duly and validly
taken. The Shares conform in all material respects to all statements with respect thereto contained in the Registration Statement and the Prospectus. All corporate action required to be taken for the authorization, issuance and sale of the Shares
have been duly and validly taken; the holders thereof are not and will not be subject to personal liability by reason of being such holders; and such Shares are not and will not be subject to the preemptive rights or rights of first refusal of any
holders of any security of the Company or similar contractual rights granted by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Validity and Binding Effect of
Agreements</U>. This Agreement has been duly and validly authorized by the Company, and, when executed and delivered, will constitute, the valid and binding agreement of the Company, enforceable against the Company in accordance with its terms,
except: (i)&nbsp;as such enforceability may be limited by bankruptcy, insolvency, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reorganization or similar laws affecting creditors&#146; rights generally; (ii)&nbsp;as enforceability of any indemnification or contribution provision may be limited under the federal and state
securities laws; and (iii)&nbsp;that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be
brought. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Capitalization</U>. The Company had, at the date or dates indicated in the Registration Statement and the Prospectus, the
duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions stated in the Registration Statement and the Prospectus. Except as set forth in, or contemplated by, the Registration Statement and the Prospectus
or grants made under any stock compensation plan in the ordinary course after the date hereof, , there are no stock options, warrants, or other rights to purchase or otherwise acquire any authorized, but unissued Common Shares of the Company or any
security convertible or exercisable into Common Shares of the Company, or any contracts or commitments to issue or sell Common Shares or any such options, warrants, rights or convertible securities </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and all ancillary documents, the
consummation by the Company of the transactions herein and therein contemplated and the compliance by the Company with the terms hereof and thereof do not and will not, with or without the giving of notice or the lapse of time or both:
(i)&nbsp;result in a breach of, or conflict with any of the terms and provisions of, or constitute a default under, or result in the creation, modification, termination or imposition of any lien, charge or encumbrance upon any material property or
assets of the Company or any of its subsidiaries pursuant to the terms of any material agreement or instrument to which the Company or any of its subsidiaries is a party; (ii)&nbsp;result in any violation of the provisions of the Company&#146;s
Certificate of Incorporation (as the same may be amended or restated from time to time, the &#147;<B>Charter</B>&#148;) or the <FONT STYLE="white-space:nowrap">by-laws</FONT> of the Company (as the same may be amended or restated from time to time)
or the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or similar organizational documents) of any of the Company&#146;s subsidiaries; or (iii)&nbsp;violate any existing applicable law, rule or regulation, or any judgment, order or
decree of any Governmental Entity as of the date hereof (including, without limitation, those promulgated by the Food and Drug Administration of the U.S. Department of Health and Human Services (the &#147;<B>FDA</B>&#148;) or by any foreign,
federal, state or local regulatory authority performing functions similar to those performed by the FDA) applicable to the Company or any of its subsidiaries or their respective assets, except, as to clauses (i)&nbsp;and (iii), where such breach,
conflict or violation would not have or reasonably be expected to result in a Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Transactions Contemplated
Herein</U>. The Company has all corporate power and authority to enter into this Agreement and to carry out the provisions and conditions hereof, and all consents, authorizations, approvals and orders required in connection therewith have been
obtained. No consent, authorization or order of, and no filing with, any court, Governmental Entity or other body is required for the valid issuance, sale and delivery of the Shares and the consummation of the transactions and agreements
contemplated by this Agreement and as contemplated by the Registration Statement and the Prospectus, except with respect to applicable federal and state securities laws and the rules and regulations of the Financial Industry Regulatory Authority,
Inc. (&#147;<B>FINRA</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Independent Accountants</U>. To the knowledge of the Company, BDO USA, P.C. (the
&#147;<B>Auditor</B>&#148;), whose report is filed with the Commission as part of the Registration Statement and the Prospectus, is an independent registered public accounting firm as required by the Securities Act and the Securities Act Regulations
and the Public Company Accounting Oversight Board. The Auditor<B> </B>has not, during the periods covered by the financial statements included in the Registration Statement and the Prospectus, provided to the Company or any of its consolidated
subsidiaries any <FONT STYLE="white-space:nowrap">non-audit</FONT> services, as such term is used in Section&nbsp;10A(g) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U>Financial Statements</U>. The financial statements, including the notes thereto and supporting schedules included in the Registration
Statement and the Prospectus, fairly present in all material respects the financial position and the results of operations of the Company and its consolidated subsidiaries at the dates and for the periods to which they apply; and such financial
statements have been prepared in conformity with U.S. generally accepted accounting principles (&#147;<B>GAAP</B>&#148;), consistently applied throughout the periods involved (provided that unaudited interim financial statements are subject to <FONT
STYLE="white-space:nowrap">year-end</FONT> audit adjustments that are not expected to be material in the aggregate and do not contain all footnotes required by GAAP); and the supporting schedules included in the Registration Statement present fairly
in all material respects the information required to be stated therein. Except as included therein, no historical or pro forma financial statements are required to be included in the Registration Statement or the Prospectus under the Securities Act.
The pro forma and pro forma as adjusted financial information and the related notes, if any, included in the Registration Statement and the Prospectus have been properly compiled and prepared in all material respects in accordance with the
applicable requirements of the Securities Act and present fairly in all material respects the information shown therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to give
effect to the transactions and circumstances referred to therein. All disclosures contained in the Registration Statement or the Prospectus regarding <FONT STYLE="white-space:nowrap">&#147;non-GAAP</FONT> financial measures&#148; (as such term is
defined by the rules and regulations of the Commission), if any, comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> of the Securities Act, to the extent
applicable. Each of the Registration Statement and the Prospectus discloses all material <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet transactions, arrangements, obligations (including contingent obligations), and other relationships of
the Company with unconsolidated entities or other persons that may have a material current or are reasonably expected to have a material future effect on the Company&#146;s financial condition, changes in financial condition, results of operations,
liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. Except as disclosed in the Registration Statement and the Prospectus, (a)&nbsp;neither the Company nor any of its subsidiaries has incurred any
material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the ordinary course of business, (b)&nbsp;neither the Company nor any its subsidiaries has declared or paid any dividends or made any
distribution of any kind with respect to its capital stock, (c)&nbsp;there has not been any change in the capital stock of the Company or any of its subsidiaries, or, other than in the ordinary course of business, any grants under any stock
compensation plan, and (d)&nbsp;there has not been any Material Adverse Change in the long-term or short-term debt of the Company or any of its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>eXtensible Business Reporting Language</U>. The interactive data in eXtensible Business Reporting Language included or incorporated by
reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Litigation; Governmental Proceedings</U>. There is no action, suit, proceeding,
inquiry, arbitration, investigation, litigation or governmental proceeding pending or, to the Company&#146;s knowledge, threatened against, or involving the Company or any of its subsidiaries or, to the Company&#146;s knowledge, any executive
officer or director which is required to be and has not been disclosed in the Registration Statement and the Prospectus or in connection with the Company&#146;s listing application for the listing of the Shares on the Exchange, except in each case
for any such action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding that would not have or reasonably be expected to result in a Material Adverse Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>No Violation or Default</U>. No material default exists in the due performance and observance of any term, covenant or condition of any
material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument evidencing an obligation for borrowed money, or any other material agreement or instrument to which the Company or
any of its subsidiaries is a party or by which the Company or any of its subsidiaries may be bound or to which any of the material properties or assets of the Company or any of its subsidiaries is subject. Neither the Company nor any of its
subsidiaries is in violation of any term or provision of its respective charter or <FONT STYLE="white-space:nowrap">by-laws.</FONT> The (or similar organizational documents). Neither the Company nor any of its subsidiaries is in violation of any
franchise, license, permit, applicable law, rule, regulation, judgment or decree of any of any Governmental Entity applicable to the Company or any of its subsidiaries, in each case, except such as would not reasonably be expected to result in a
Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <U>Conduct of Business</U>. Except as described in the Registration Statement and the Prospectus, the
Company and each of its subsidiaries has all requisite corporate power (or similar entity) and authority, and has all necessary material authorizations, approvals, orders, licenses, certificates and permits of and from all governmental regulatory
officials and bodies that it needs as of the date hereof to conduct their respective businesses as currently being conducted as described in the Registration Statement and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>Regulatory</U>. All preclinical studies and clinical trials conducted by or to the knowledge of the Company, on behalf of the Company
that are material to the Company, are or have been adequately described in the Registration Statement and the Prospectus in all material respects. The clinical trials and preclinical studies conducted by or, to the knowledge of the Company, on
behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus were and, if still ongoing, are being conducted in material compliance
with all laws and regulations applicable thereto in the jurisdictions in which they are being conducted. The descriptions in the Registration Statement and the Prospectus of the results of such studies and trials are accurate and complete in all
material respects and fairly present the data derived from such studies and trials, and the Company has no knowledge of, any clinical trial or preclinical study the results of which are inconsistent with or otherwise call into question the results
of any clinical trial or preclinical study conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Registration Statement and the Prospectus. Except as disclosed in the Registration Statement and the Prospectus, the Company has not received any written notices from the FDA, the European
Medicines Agency (&#147;<B>EMA</B>&#148;) or any other Governmental Entity requiring, requesting or suggesting termination, suspension, imposition of a clinical hold (which has not been remedied) or material modification for or of any clinical trial
or preclinical study that is described in the Registration Statement, the and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus. Except as disclosed in the Registration Statement and the
Prospectus, the Company has not received any written notices from any Governmental Entity, and otherwise has no knowledge of, or reason to believe that any license, approval, permit or authorization to conduct any clinical trial of any potential
product of the Company has been, will be or may be suspended, revoked, modified or limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <U>Compliance with Laws</U>. Except as
disclosed in the Registration Statement and the Prospectus, the Company and each of its subsidiaries: (A)&nbsp;is and at all times has been in compliance with all statutes, rules, or regulations, including the Federal Food Drug and Cosmetic Act, 21
U.S.C. &#167;&#167; 301 et seq.; Title XVIII of the Social Security Act, 42 U.S.C. &#167;&#167; 1395-1395lll (the Medicare statute); Title XIX of the Social Security Act, 42 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">1396-1396w-5</FONT>
(the Medicaid statute); the Federal Anti-Kickback Statute, 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b);</FONT> the civil False Claims Act, 31 U.S.C. &#167;&#167; 3729 et seq.; the criminal False Claims Act 42 U.S.C. <FONT
STYLE="white-space:nowrap">1320a-7b(a);</FONT> the criminal laws relating to health care fraud and abuse, including 18 U.S.C. Sections 286 and 287 and the health care fraud criminal provisions under the Health Insurance Portability and
Accountability Act of 1996, 42 U.S.C. &#167;&#167; 1320d et seq., (&#147;HIPAA&#148;); the Civil Monetary Penalties Law, 42 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">1320a-7a;</FONT> the Physician Payments Sunshine Act, 42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7h;</FONT> the exclusion law, 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7;</FONT> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, 42 U.S.C. &#167;&#167;
17921 et seq.; the Public Health Service Act, 42 U.S.C. &#167;&#167; 201 et seq.; the regulations promulgated pursuant to such laws; and any similar federal, state, local and foreign laws and regulations of any Governmental Entity applicable to the
ownership, testing, development, use, marketing, labeling, promotion, offer for sale, or performance of any product being developed by the Company or any of its subsidiaries (&#147;<B>Applicable Laws</B>&#148;), except as would not, individually or
in the aggregate, reasonably be expected to have a Material Adverse Change; (B)&nbsp;has not received any FDA Form 483, warning letter, or other written correspondence or notice from the FDA or any other Governmental Entity alleging or asserting
material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&#147;Authorizations&#148;); (C) possesses all
material Authorizations and such Authorizations are valid and in full force and effect and neither the Company nor any of its subsidiaries is in material violation of any term of any such Authorizations; (D)&nbsp;has not received written notice of
any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Entity alleging that any product or activity is in material violation of any Applicable Laws or Authorizations; (E)&nbsp;has
not received written notice that any Governmental Entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations; (F)&nbsp;has filed, obtained, maintained or submitted all material reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments were complete and correct in all material respects on the date filed (or were corrected or supplemented by a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subsequent submission); (G) along with its employees, officers and directors, and to the Company&#146;s knowledge, independent contractors and agents, is not a party to or has any ongoing
reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any governmental authority
including any regulatory agencies; and (H)&nbsp;along with its employees, officers and directors, independent contractors and agents, has not been excluded, suspended or debarred from, or otherwise ineligible for participation in any government
health care program or human clinical research. Neither the Company nor any of its subsidiaries has reported or received reports of any serious, unexpected adverse event associated with any investigational product of Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <U>Investment Company Act</U>. Neither the Company nor any of its subsidiaries is and, after giving effect to the offering and the
application of the proceeds thereof as described in the Registration Statement and the Prospectus, will be, required to register as an &#147;investment company,&#148; as defined in the Investment Company Act of 1940, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <U>No Price Stabilization or Manipulation; Compliance with Regulation M</U>. Neither the Company nor any of its subsidiaries nor, to the
Company&#146;s knowledge, any of their respective officers, directors or Affiliates has taken or will take, directly or indirectly, any action designed to or intended to stabilize or manipulate the price of any security of the Company, or which
caused or resulted in, or which would in the future reasonably be expected to cause or result in stabilization or manipulation of the price of the Common Shares or any other &#147;reference security&#148; (as defined in Rule 100 of Regulation M
under the Exchange Act (<B>&#147;Regulation M&#148;</B>)) whether to facilitate the sale or resale of the Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation M. The Company acknowledges that the Agent
may engage in passive market making transactions in the Shares on the Principal Market in accordance with Regulation M. The Common Shares are &#147;actively traded securities&#148; (as defined in Regulation&nbsp;M). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <U>Intellectual Property</U>. The Company and each of its subsidiaries own or possess or have valid rights to use or can develop or
acquire on reasonable terms all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions, trade secrets and similar rights necessary for the conduct
of the business of the Company and its subsidiaries, as applicable, as currently carried on and as described in the Registration Statement and the Prospectus (&#147;<B>Intellectual Property Rights</B>&#148;). To the knowledge of the Company, no
action or use by the Company or any of its subsidiaries necessary for the conduct of their respective businesses as currently carried on and as described in the Registration Statement and the Prospectus will involve or give rise to any infringement
of any Intellectual Property Rights of others. Neither the Company nor any of its subsidiaries has received any written notice alleging any such infringement or conflict with asserted Intellectual Property Rights of others. Except as would not
reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change (A)&nbsp;to the knowledge of the Company, (i)&nbsp;except as may be disclosed in the Registration Statement and the Prospectus, there are no third
parties who have rights to any of the Intellectual Property Rights owned by the Company or any of its subsidiaries, except for customary reversionary rights of third-party licensors with respect to Intellectual Property; and (ii)&nbsp;there is no
infringement, misappropriation or violation by third parties of any of the Intellectual Property Rights owned by the Company or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any of its subsidiaries; (B)&nbsp;there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the rights of the Company or any of
its subsidiaries in or to any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (C)&nbsp;the Intellectual Property Rights owned by the Company or any of its
subsidiaries and, to the knowledge of the Company, the Intellectual Property Rights licensed to the Company or any of its subsidiaries have not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and
there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property Rights, and the Company is unaware of any facts which would form a
reasonable basis for any such claim; (D)&nbsp;there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others that the Company or any of its subsidiaries infringes, misappropriates or otherwise
violates any Intellectual Property Rights or other proprietary rights of others, the Company has not received any written notice of such claim and the Company is unaware of any other facts which would form a reasonable basis for any such claim;
(E)&nbsp;to the Company&#146;s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property Rights owned by or licensed to the Company or any of its subsidiaries; and (F)&nbsp;to the
Company&#146;s knowledge, no employee of the Company or any of its subsidiaries is in or has ever been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement,
<FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation
relates to such employee&#146;s employment with the Company or any of its subsidiaries, or actions undertaken by the employee while employed with the Company or any of its subsidiaries. To the Company&#146;s knowledge, all material technical
information developed by and belonging to the Company or any of its subsidiaries which has not been patented has been kept confidential. Neither the Company nor any of its subsidiaries is a party to or bound by any options, licenses or agreements
with respect to the Intellectual Property Rights of any other person or entity that are required to be set forth in the Registration Statement and the Prospectus and are not materially described therein. The Registration Statement and the Prospectus
contain in all material respects the same description of the matters set forth in the preceding sentence. The Company and each of its subsidiaries have complied in all material respects with the terms of each agreement pursuant to which Intellectual
Property Rights have been optioned or licensed to the Company or any of its subsidiaries, and, to the Company&#146;s knowledge, all such agreements are in full force and effect. None of the technology employed by the Company or any of its
subsidiaries has been obtained or is being used by the Company or any of its subsidiaries in violation of any contractual obligation binding on the Company or any of its subsidiaries or, to the Company&#146;s knowledge, any of their respective
officers, directors or employees, or otherwise in violation of the rights of any persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <U>Title to Real and Personal
Property</U>. The Company and each of its subsidiaries have good and marketable title in fee simple (in the case of real property) to, or have valid and marketable rights to lease or otherwise use, all items of real or personal property which are
material to the business of the Company or any of its subsidiaries, in each case free and clear of all liens, encumbrances, security interests, claims and defects that (i)&nbsp;do not, singularly or in the aggregate, materially affect the value of
such property and do not materially interfere with the use made and proposed to be made of such property by the Company or any of its subsidiaries or (ii)&nbsp;would not reasonably be expected, singularly or in the aggregate, to have a Material
Adverse Change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <U>No Labor Dispute</U>. No labor dispute with the employees of the Company or any of
its subsidiaries exists or, to the knowledge of the Company, is imminent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <U>Compliance with ERISA</U>. The Company and any
&#147;employee benefit plan&#148; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &#147;<B>ERISA</B>&#148;)) established or maintained by
the Company or its &#147;ERISA Affiliates&#148; (as defined below) are in compliance in all material respects with ERISA. &#147;<B>ERISA Affiliate</B>&#148; means, with respect to the Company, any member of any group of organizations described in
Sections 414(b),(c),(m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the &#147;<B>Code</B>&#148;) of which the Company is a member. No &#147;reportable event&#148; (as
defined under ERISA) has occurred or is reasonably expected to occur with respect to any &#147;employee benefit plan&#148; established or maintained by the Company or any of its ERISA Affiliates. No &#147;employee benefit plan&#148; established or
maintained by the Company or any of its ERISA Affiliates, if such &#147;employee benefit plan&#148; were terminated, would have any material &#147;amount of unfunded benefit liabilities&#148; (as defined under ERISA). Neither the Company nor any of
its ERISA Affiliates has incurred or reasonably expects to incur any material liability under (i)&nbsp;Title IV of ERISA with respect to termination of, or withdrawal from, any &#147;employee benefit plan&#148; or (ii)&nbsp;Sections 412, 4971, 4975
or 4980B of the Code. Each &#147;employee benefit plan&#148; established or maintained by the Company or any of its ERISA Affiliates that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified and, to the knowledge of the
Company, nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff)
<U>Environmental Laws and Hazardous Materials</U>. Except as otherwise described in the Registration Statement, and the Prospectus, and except as would not, individually or in the aggregate, result in a Material Adverse Change, the Company and each
of its subsidiaries is in compliance with all foreign, federal, state and local rules, laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety or the
environment which are applicable to their businesses (&#147;<B>Environmental Laws</B>&#148;). There has been no storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other
wastes or other hazardous substances by, due to, or caused by the Company or any of its subsidiaries (or, to the Company&#146;s knowledge, any other entity for whose acts or omissions the Company or any of its subsidiaries is or may otherwise be
liable) upon any of the property now or previously owned or leased by the Company or any of its subsidiaries, or upon any other property, in violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which
would, under any law, statute, ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any liability, which would individually or in the aggregate, result in a Material Adverse Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <U>Taxes</U>. The Company and each of its subsidiaries have filed all material returns (as hereinafter defined) required to be filed with
taxing authorities prior to the date hereof or have duly obtained extensions of time for the filing thereof. The Company and each of its subsidiaries have paid all taxes (as hereinafter defined) shown as due on such returns that were
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
filed and have paid all taxes imposed on or assessed against the Company or any of its subsidiaries. The provisions for taxes payable, if any, shown on the financial statements filed with or as
part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such consolidated financial statements. Except as disclosed in writing to the Agent,
(i)&nbsp;no issues have been raised (and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted as due from the Company or any of its subsidiaries, and (ii)&nbsp;no waivers of statutes of limitation
with respect to the returns or collection of taxes have been given by or requested from the Company or any of its subsidiaries. The term &#147;taxes&#148; mean all federal, state, local, foreign and other net income, gross income, gross receipts,
sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees,
assessments or charges of any kind whatever, together with any interest and any penalties, additions to tax or additional amounts with respect thereto. The term &#147;returns&#148; means all returns, declarations, reports, statements and other
documents required to be filed in respect to taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <U>Insurance</U>. The Company and each of its subsidiaries carry or are entitled
to the benefits of insurance, with reputable insurers, and in such amounts and covering such risks which the Company believes are reasonably adequate, and all such insurance is in full force and effect. The Company has no reason to believe that it
or any of its subsidiaries will not be able (i)&nbsp;to renew their respective existing insurance coverage as and when such policies expire or (ii)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate to
conduct their respective businesses as now conducted and at a cost that would not result in a Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Accounting
Controls</U>. The Company and each of its subsidiaries maintain a system of &#147;internal control over financial reporting&#148; (as defined under Rules <FONT STYLE="white-space:nowrap">13a-15</FONT> and
<FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act Regulations) that, if any, have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar
functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls
sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the
Registration Statement and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. Except as disclosed in the Registration
Statement and the Prospectus, the Company is not aware of any material weaknesses, if any, in the internal controls of the Company or any of its subsidiaries. The Company&#146;s auditors and the Audit Committee of the Board of Directors of the
Company have been advised of: (i)&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are known to the Company&#146;s management and that have adversely affected or
are reasonably </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
likely to adversely affect the Company&#146;s or any of its subsidiaries&#146; ability to record, process, summarize and report financial information; and (ii)&nbsp;any fraud, if any, known to
the Company&#146;s management, whether or not material, that involves management or other employees who have a significant role in the Company&#146;s or any of its subsidiaries&#146; internal controls over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <U>Disclosure Controls</U>. The Company and each of its subsidiaries have developed and currently maintain disclosure controls and
procedures that will comply with Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> or <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act applicable to it, and such controls and procedures are effective to ensure that all
material information concerning the Company or its subsidiaries, as applicable, will be made known on a timely basis to the individuals responsible for the preparation of the Company&#146;s Exchange Act filings and other public disclosure documents.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <U>Officers&#146; Certificate</U>. Any certificate signed by any duly authorized officer of the Company and delivered to you or to
counsel for the Agent shall be deemed a representation and warranty by the Company to the Agent as to the matters covered thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll)
<U>Subsidiaries</U>. The Company has no significant subsidiaries as defined by Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> other than the subsidiaries listed in Exhibit 21 to the
Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <U>Related Party Transactions</U>.
There are no business relationships or related party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement and the Prospectus that have not been described as
required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <U>Registration Rights of Third Parties</U>. Except as has been previously validly waived or as set forth in the
Registration Statement and the Prospectus, no holders of any securities of the Company or any rights exercisable for or convertible or exchangeable into securities of the Company have the right to require the Company to register any such securities
of the Company under the Securities Act or to include any such securities in a registration statement to be filed by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo)
<U>Margin Securities</U>. The Company owns no &#147;margin securities&#148; as that term is defined in Regulation U of the Board of Governors of the Federal Reserve System (the &#147;<B>Federal Reserve Board</B>&#148;), and none of the proceeds of
Offering will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for any
other purpose which would reasonably be expected to cause any of the Common Shares to be considered a &#147;purpose credit&#148; within the meanings of Regulation T, U or X of the Federal Reserve Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <U>Finder&#146;s Fees</U>. Except as described in the Registration Statement and the Prospectus, there are no claims, payments,
arrangements, agreements or understandings relating to the payment of a finder&#146;s, consulting or origination fee by the Company, any of its subsidiaries or, to the Company&#146;s knowledge, any insider with respect to the sale of the Shares
hereunder or any other arrangements, agreements or understandings of the Company or any of its subsidiaries or, to the Company&#146;s knowledge, any of their respective stockholders that may affect the Agent&#146;s compensation, as determined by
FINRA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <U>Listing</U>. The Company is subject to and in compliance in all material respects
with the reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act. The Common Shares are registered pursuant to Section&nbsp;12(b) or 12(g) of the Exchange and is listed on The Nasdaq Capital Market (the
&#147;<B>Exchange</B>&#148;), and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Shares under the Exchange Act or delisting the Common Shares from the Exchange, nor
has the Company received any notification that the Commission or FINRA is contemplating terminating such registration or listing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr)
<U>Stop Orders, etc</U>. Neither the Commission nor, to the Company&#146;s knowledge, any state regulatory authority has issued any order preventing or suspending the use of the Registration Statement or the Prospectus, or has instituted or, to the
Company&#146;s knowledge, threatened to institute, any proceedings with respect to such an order. The Company has complied in all material respects with each request (if any) from the Commission for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <U>Board of Directors</U>. The qualifications of the persons serving as board members and the overall composition of the board comply
with the Exchange Act, the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder (the &#147;<B>Sarbanes-Oxley Act</B>&#148;) applicable to the Company and the listing rules of the Exchange. At least one member of the Audit Committee of the
Board of Directors of the Company qualifies as an &#147;audit committee financial expert,&#148; as such term is defined under Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> and the listing rules of the Exchange. In addition, at least a
majority of the persons serving on the Board of Directors qualify as &#147;independent,&#148; as defined under the listing rules of the Exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <U>Sarbanes-Oxley Compliance</U>. The Company is in material compliance with the provisions of the Sarbanes-Oxley Act applicable to it,
and has implemented or will implement such programs and taken reasonable steps to ensure the Company&#146;s future compliance (not later than the relevant statutory and regulatory deadlines therefor) with all of the material provisions of the
Sarbanes-Oxley Act </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <U>Payments Within Twelve (12)</U><U></U><U>&nbsp;Months</U>. Except as described in the Registration Statement
and the Prospectus, neither the Company nor any of its subsidiaries has made any direct or indirect payments (in cash, securities or otherwise) to: (i)&nbsp;any person, as a finder&#146;s fee, consulting fee or otherwise, in consideration of such
person raising capital for the Company or introducing to the Company persons who raised or provided capital to the Company; (ii)&nbsp;any FINRA member; or (iii)&nbsp;any person or entity that has any direct or indirect affiliation or association
with any FINRA member, within the twelve (12)&nbsp;months prior to the date hereof, other than the payment to the Agent as provided hereunder in connection with the offering of the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <U>No Improper Practices</U>. (i)&nbsp;Neither the Company nor any of its subsidiaries
nor, to the Company&#146;s knowledge, any director, officer, or employee of the Company or any of its subsidiaries, agent, Affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the past five years, made any
unlawful contributions to any candidate for any political office (or failed fully to disclose any contribution in violation of applicable law) or made any contribution or other payment to any official of, or candidate for, any federal, state,
municipal, or foreign office or other person charged with similar public or quasi-public duty in violation of any applicable law or of the character required to be disclosed in the Prospectus; (ii)&nbsp;no relationship, direct or indirect, exists
between or among the Company or any of its subsidiaries or, to the Company&#146;s knowledge, any Affiliate of the Company or any of its subsidiaries, on the one hand, and the directors, officers and stockholders of the Company, on the other hand,
that is required by the Securities Act to be described in the Registration Statement and the Prospectus that is not so described; (iii)&nbsp;no relationship, direct or indirect, exists between or among the Company or any of its subsidiaries or any
Affiliate of the Company or any of its subsidiaries, on the one hand, and the directors, officers, or stockholders of the Company, on the other hand, that is required by the rules of FINRA to be described in the Registration Statement and the
Prospectus that is not so described; (iv)&nbsp;except as described in the Registration Statement and the Prospectus, there are no material outstanding loans or advances or material guarantees of indebtedness by the Company or any of its subsidiaries
to or for the benefit of any of their respective officers or directors or any of the members of the families of any of them; and (v)&nbsp;neither Company nor or any of its subsidiaries has offered, or caused any placement agent to offer, Common
Shares to any person with the intent to influence unlawfully (A)&nbsp;a customer or supplier of the Company or any of its subsidiaries to alter the customer&#146;s or supplier&#146;s level or type of business with the Company or any of its
subsidiaries or (B)&nbsp;a trade journalist or publication to write or publish favorable information about the Company or any of its subsidiaries or any of their respective products or services, and, (vi)&nbsp;neither the Company nor or any of its
subsidiaries nor, to the Company&#146;s knowledge, any director, officer or employee of the Company or any of its subsidiaries, agent, Affiliate or other person acting on behalf of the Company or any of its subsidiaries has (A)&nbsp;violated or is
in violation of any applicable provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or any other applicable anti-bribery or anti-corruption law (collectively, &#147;<B>Anti-Corruption Laws</B>&#148;), (B) unlawfully promised,
offered, provided, attempted to provide or authorized the provision of anything of value, directly or indirectly, to any person for the purpose of obtaining or retaining business, influencing any act or decision of the recipient or securing any
improper advantage, or (C)&nbsp;made any payment of funds of the Company or any of its subsidiaries or received or retained any funds in violation of any Anti-Corruption Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) <U>Industry Data</U>. The statistical and market-related data included in each of the Registration Statement and the Prospectus are based
on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate or represent the Company&#146;s good faith estimates that are made on the basis of data derived from such sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) <U>Operations</U>. The operations of the Company and each of its subsidiaries are and have been conducted at all times in compliance with
applicable financial record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or any of its subsidiaries is subject,
the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &#147;<B>Money Laundering Laws</B>&#148;); and no action, suit or
proceeding by or before any Governmental Entity involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy) <U>Sanctions</U>. (i)&nbsp;The Company represents that, neither the Company nor any of
its subsidiaries nor, to the Company&#146;s knowledge, any director, officer, employee, agent, Affiliate or representative of the Company or any of its subsidiaries, is a government, individual, or entity (in this paragraph (yy),
&#147;<B>Person</B>&#148;) that is, or is owned or controlled by a Person that is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#146;s Office of
Foreign Assets Control (&#147;<B>OFAC</B>&#148;), the United Nations Security Council, the European Union, His Majesty&#146;s Treasury, or other relevant sanctions authorities, including, without limitation, designation on OFAC&#146;s Specially
Designated Nationals and Blocked Persons List or OFAC&#146;s Foreign Sanctions Evaders List (as amended, collectively, &#147;<B>Sanctions</B>&#148;), nor </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">located, organized or resident in a country or territory that is the subject of Sanctions that broadly prohibit
dealings with that country or territory (including, without limitation, Cuba, Iran, North Korea, Syria, the Crimea Region of Ukraine, <FONT STYLE="white-space:nowrap">the&nbsp;so-called&nbsp;Donetsk</FONT> People&#146;s Republic Region of Ukraine
and <FONT STYLE="white-space:nowrap">the&nbsp;so-called&nbsp;Luhansk</FONT> People&#146;s Republic Region of Ukraine) (the &#147;<B>Sanctioned Countries</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) The Company represents and covenants that neither it nor any of its subsidiaries will, directly or indirectly, use the proceeds of the offering, or lend,
contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fund or facilitate any activities or business of or with any Person or in any country or territory that, at
the time of such funding or facilitation, is the subject of Sanctions or is a Sanctioned Country; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other manner that will result in a violation of Sanctions by any Person (including any Person
participating in the offering, whether as underwriter, advisor, investor or otherwise). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iii) The Company represents and covenants
that, for the past 10 years, neither it nor any of its subsidiaries has engaged in, is now engaging in, and will engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction
is or was the subject of Sanctions or is or was a Sanctioned Country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(zz) <U>Transactions Affecting Disclosure to FINRA</U>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Use of Proceeds</U>. None of the net proceeds of the offering will be paid by the Company to any
participating FINRA member or its Affiliates, except as specifically authorized herein. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>FINRA Affiliation</U>. Except as set forth in the Registration Statement and the Prospectus, there is no
(i)&nbsp;officer or director of the Company, (ii)&nbsp;beneficial owner of 5% or more of any class of the Company&#146;s securities or (iii)&nbsp;beneficial owner of the Company&#146;s unregistered equity securities which were acquired during the <FONT
STYLE="white-space:nowrap">180-day</FONT> period immediately preceding the filing of the Registration Statement that is an Affiliate or associated person of a FINRA member participating in the Offering (as determined in accordance with the rules and
regulations of FINRA). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aaa) <U>Cybersecurity</U>. (i)&nbsp;Except as may be included or incorporated by reference in
the Registration Statement and the Prospectus, (A)&nbsp;to the Company&#146;s knowledge, there has been no material security breach or other material compromise of or relating to any of the Company&#146;s information technology and computer systems,
networks, hardware, software, data (including the data of their respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of them), equipment or technology (collectively, &#147;<B>IT Systems and
Data</B>&#148;) and (B)&nbsp;the Company has not been notified of, and have no knowledge of any event or condition that would reasonably be expected to result in, any material security breach or other material compromise to their IT Systems and
Data; (ii)&nbsp;the Company is presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual
obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, in the case of this clause (ii),
individually or in the aggregate, result in a Material Adverse Change; and (iii)&nbsp;the Company has implemented backup and disaster recovery technology consistent with industry standards and practices </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bbb) <U>Privacy</U>. Except as otherwise disclosed in the Registration Statement and the Prospectus or as would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect, (i)&nbsp;the Company and its subsidiaries at all times have been, and are presently, in compliance with all applicable state and federal data privacy and security laws and
regulations, including without limitation HIPAA, (ii)&nbsp;the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May&nbsp;25, 2018, have been and currently are in compliance with, the
European Union General Data Protection Regulation (&#147;<B>GDPR&#148;)</B> (EU 2016/679), and (iii)&nbsp;the Company and its subsidiaries, are currently taking or have taken commercially reasonable actions to prepare to comply with all applicable
laws and regulations with respect to Personal Data (defined below) (collectively, the &#147;<B>Privacy Laws</B>&#148;). &#147;<B>Personal Data</B>&#148; means (i)&nbsp;a natural person&#146;s name, street address, telephone number, <FONT
STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit card number, bank information, or customer or account number; (ii)&nbsp;any
information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii)&nbsp;Protected Health Information as defined by HIPAA; (iv) &#147;personal data&#148; as defined by GDPR; and
(v)&nbsp;any other piece of information that identifies such natural person. Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, at all times in the past three years, the Company and its
subsidiaries have made all disclosures to users or customers required by applicable Privacy Laws and regulatory rules or requirements. None of such disclosures made or contained in any policy have, to the knowledge of the Company, been inaccurate or
in violation of any applicable laws and regulatory rules or requirements in any material respect. Except as otherwise disclosed in the Registration Statement and the Prospectus or as would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect, neither the Company nor any of its subsidiaries (i)&nbsp;has received notice of any actual or potential liability under or relating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to, or actual or potential violation of, any of the Privacy Laws, or has knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently
conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree or agreement that imposes any obligation or liability under any
Privacy Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ccc) <U>Market Capitalization</U>. At the time the Registration Statement was originally declared effective, the Company
met the then applicable requirements for the use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, including, but not limited to, General Instruction I.B.1 or I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> The
Company is eligible to use Form <FONT STYLE="white-space:nowrap">S-3</FONT> for the proposed offering of the Shares, including the transaction requirements set forth in General Instruction 1.B.1 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT>
The Company meets the definition of &#147;experienced issuer&#148; as defined in FINRA Rule 5110(j)(6). The Company is not a shell company (as defined in Rule 405 under the Securities Act) and has not been a shell company for at least 12 calendar
months previously. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by any officer or representative of the Company or any of its subsidiaries and delivered to the
Agent or counsel for the Agent in connection with an issuance of Shares shall be deemed a representation and warranty by the Company to the Agent as to the matters covered thereby on the date of such certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges that the Agent and, for purposes of the opinions to be delivered pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U>
hereof, counsel to the Company and counsel to the Agent, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3. ISSUANCE AND SALE OF COMMON SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Sale of Securities</U>. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and
conditions herein set forth, the Company and the Agent agree that the Company may from time to time seek to sell Shares through the Agent, acting as sales agent, or directly to the Agent, acting as principal, as follows, with an aggregate Sales
Price of up to the Maximum Program Amount, based on and in accordance with Issuance Notices as the Company may deliver, during the Agency Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Mechanics of Issuances</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Issuance Notice</U>. Upon the terms and subject to the conditions set forth herein, on any Trading Day during the Agency Period on
which the conditions set forth in <U>Section</U><U></U><U>&nbsp;5(a)</U> and <U>Section</U><U></U><U>&nbsp;5(b)</U> shall have been satisfied, the Company may exercise its right to request an issuance of Shares by delivering to the Agent an Issuance
Notice; <I>provided, however</I>, that (A)&nbsp;in no event may the Company deliver an Issuance Notice to the extent that the sum of (x)&nbsp;the aggregate Sales Price of the requested Issuance Amount, plus (y)&nbsp;the aggregate Sales Price of all
Shares issued under all previous Issuance Notices effected pursuant to this Agreement, would exceed the Maximum Program Amount; and (B)&nbsp;prior to delivery of any Issuance Notice, the period set forth for any previous Issuance Notice shall have
expired or been terminated. An Issuance Notice shall be considered delivered on the Trading Day that it is received by <FONT STYLE="white-space:nowrap">e-mail</FONT> to the persons set forth in Schedule A hereto and confirmed by the Company by
telephone (including a voicemail message to the persons so identified), with the understanding that, with adequate prior written notice, the Agent may modify the list of such persons from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Agent Efforts</U>. Upon the terms and subject to the conditions set forth in this
Agreement, upon the receipt of an Issuance Notice, the Agent will use its commercially reasonable efforts consistent with its normal sales and trading practices to place the Shares with respect to which the Agent has agreed to act as sales agent,
subject to, and in accordance with the information specified in, the Issuance Notice, unless the sale of the Shares described therein has been suspended, cancelled or otherwise terminated in accordance with the terms of this Agreement. For the
avoidance of doubt, the parties to this Agreement may modify an Issuance Notice at any time provided they both agree in writing to any such modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Method of Offer and Sale</U>. The Shares may be offered and sold (A)&nbsp;in negotiated transactions with the consent of the Company
or (B)&nbsp;by any other method permitted by law deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4) under the Securities Act, including block transactions, sales made directly on the Principal Market or sales made into
any other existing trading market of the Common Shares. Nothing in this Agreement shall be deemed to require either party to agree to the method of offer and sale specified in the preceding sentence, and (except as specified in clause
(A)&nbsp;above) the method of placement of any Shares by the Agent shall be at the Agent&#146;s discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U>Confirmation to the
Company</U>. If acting as sales agent hereunder, the Agent will provide written confirmation to the Company no later than the opening of the next Trading Day following the Trading Day on which it has placed Shares hereunder setting forth the number
of shares sold on such Trading Day, the corresponding Sales Price and the Issuance Price payable to the Company in respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)
<U>Settlement</U>. Each issuance of Shares will be settled on the applicable Settlement Date for such issuance of Shares and, subject to the provisions of <U>Section</U><U></U><U>&nbsp;5</U>, on or before each Settlement Date, the Company will, or
will cause its transfer agent to, electronically transfer the Shares being sold by crediting the Agent or its designee&#146;s account at The Depository Trust Company through its Deposit/Withdrawal At Custodian (DWAC) System, or by such other means
of delivery as may be mutually agreed upon by the parties hereto and, upon receipt of such Shares, which in all cases shall be freely tradable, transferable, registered shares in good deliverable form, the Agent will deliver, by wire transfer of
immediately available funds, the related Issuance Price in same day funds delivered to an account designated by the Company prior to the Settlement Date. The Company may sell Shares to the Agent as principal at a price agreed upon at each relevant
time Shares are sold pursuant to this Agreement (each, a &#147;<B>Time of Sale</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <U>Suspension or Termination of
Sales</U>. Consistent with standard market settlement practices, the Company or the Agent may, upon notice to the other party hereto in writing or by telephone (confirmed immediately by verifiable email), suspend any sale of Shares, and the period
set forth in an Issuance Notice shall immediately terminate; <I>provided, however</I>, that (A)&nbsp;such suspension and termination shall not affect or impair either party&#146;s obligations with respect to any Shares placed or sold hereunder prior
to the receipt of such notice; (B)&nbsp;if the Company suspends or terminates any sale of Shares after the Agent confirms such sale to the Company, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company shall still be obligated to comply with <U>Section</U><U></U><U>&nbsp;3(b)(v)</U> with respect to such Shares; and (C)&nbsp;if the Company defaults in its obligation to deliver Shares on
a Settlement Date, the Company agrees that it will hold the Agent harmless against any loss, claim, damage or expense (including, without limitation, penalties, interest and reasonable legal fees and expenses), as incurred, arising out of or in
connection with such default by the Company. The parties hereto acknowledge and agree that, in performing its obligations under this Agreement, the Agent may borrow Common Shares from stock lenders in the event that the Company has not delivered
Shares to settle sales as required by subsection (v)&nbsp;above, and may use the Shares to settle or close out such borrowings. The Company agrees that no such notice shall be effective against the Agent unless it is made to the persons identified
in writing by the Agent pursuant to <U>Section</U><U></U><U>&nbsp;3(b)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) <U>No Guarantee of Placement, Etc.</U> The Company
acknowledges and agrees that (A)&nbsp;there can be no assurance that the Agent will be successful in placing Shares; (B)&nbsp;the Agent will incur no liability or obligation to the Company or any other Person if it does not sell Shares; and
(C)&nbsp;the Agent shall be under no obligation to purchase Shares on a principal basis pursuant to this Agreement, except as otherwise specifically agreed by the Agent and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) <U>Material <FONT STYLE="white-space:nowrap">Non-Public</FONT> Information.</U> Notwithstanding any other provision of this Agreement,
the Company and the Agent agree that the Company shall not deliver any Issuance Notice to the Agent, and the Agent shall not be obligated to place any Shares, during any period in which the Company is in possession of material <FONT
STYLE="white-space:nowrap">non-public</FONT> information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Fees</U>. As compensation for services rendered, the Company shall pay
to the Agent, on the applicable Settlement Date, the Selling Commission for the applicable Issuance Amount (including with respect to any suspended or terminated sale pursuant to <U>Section</U><U></U><U>&nbsp;3(b)(vi))</U> by the Agent deducting the
Selling Commission from the applicable Issuance Amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Expenses</U>. The Company agrees to pay all costs, fees and expenses
incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses incident to the issuance and delivery of the Shares (including
all printing and engraving costs); (ii)&nbsp;all fees and expenses of the registrar and transfer agent of the Shares; (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Shares;
(iv)&nbsp;all fees and expenses of the Company&#146;s counsel, independent public or certified public accountants and other advisors; (v)&nbsp;all costs and expenses incurred in connection with the preparation, printing, filing, shipping and
distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Prospectus, any Free Writing Prospectus (as defined below) prepared by or on behalf of, used by, or referred
to by the Company, and all amendments and supplements thereto, and this Agreement; (vi)&nbsp;all filing fees, attorneys&#146; fees and expenses incurred by the Company or the Agent in connection with qualifying or registering (or obtaining
exemptions from the qualification or registration of) all or any part of the Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Agent, preparing and printing a
&#147;<B>Blue Sky Survey</B>&#148; or memorandum and a &#147;Canadian wrapper&#148;, and any supplements thereto, advising the Agent of such qualifications, registrations, determinations and exemptions; (vii)&nbsp;the reasonable fees and
disbursements of the Agent&#146;s counsel, including&nbsp;the reasonable fees and expenses of counsel for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Agent in connection with, FINRA review, if any, and approval of the Agent&#146;s participation in the offering and distribution of the Shares; (viii)&nbsp;the filing fees incident to FINRA
review, if any; (ix)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses
associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with
the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and of the Agent and any such consultants, and the cost of any aircraft chartered in connection with the road show; and
(x)&nbsp;the fees and expenses associated with listing the Shares on the Principal Market. The fees and disbursements of Agent&#146;s counsel pursuant to subsections (vi)&nbsp;and (vii) above shall not exceed (A) $75,000 in connection with execution
of this Agreement, (B) $25,000 in connection with each Triggering Event Date (as defined below) involving the filing of a Form <FONT STYLE="white-space:nowrap">10-K</FONT> on which the Company is required to provide a certificate pursuant to
Section&nbsp;4(o) and (C) $15,000 in connection with each other Triggering Event Date (as defined below) on which the Company is required to provide a certificate pursuant to Section&nbsp;4(o). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4. ADDITIONAL COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company covenants and agrees with the Agent as follows, in addition to any other covenants and agreements made elsewhere in this
Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Exchange Act Compliance</U>. During the Agency Period, the Company shall (i)&nbsp;file, on a timely basis, with the
Commission all reports and documents required to be filed under Section&nbsp;13, 14 or 15 of the Exchange Act in the manner and within the time periods required by the Exchange Act; and (ii)&nbsp;in the Company&#146;s sole discretion, either
(A)&nbsp;include in its quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and its annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> a summary detailing, for the relevant reporting period, (1)&nbsp;the number
of Shares sold through the Agent pursuant to this Agreement and (2)&nbsp;the net proceeds received by the Company from such sales or (B)&nbsp;prepare a prospectus supplement containing, or include in such other filing permitted by the Securities Act
or Exchange Act (each an &#147;<B>Interim Prospectus Supplement</B>&#148;), such summary information and, at least once a quarter and subject to this Section&nbsp;4, file such Interim Prospectus Supplement pursuant to Rule 424(b) under the
Securities Act (and within the time periods required by Rule 424(b) and Rule 430B under the Securities Act)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Securities Act
Compliance</U>. After the date of this Agreement, the Company shall promptly advise the Agent in writing (i)&nbsp;of the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii)&nbsp;of the time
and date of any filing of any post-effective amendment to the Registration Statement, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus, any Free Writing Prospectus; (iii)&nbsp;of the time and date that any
post-effective amendment to the Registration Statement or any Rule 462(b) Registration Statement becomes effective; and (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment thereto, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus or of any order preventing or suspending the use of any Free Writing Prospectus or the Prospectus, or of any proceedings to
remove, suspend or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terminate from listing or quotation the Common Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or
initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time, the Company will use its reasonable best efforts to obtain the lifting of such order as soon as practicable. Additionally, the
Company agrees that it shall comply with the provisions of Rule 424(b) and Rule 433, as applicable, under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) or Rule 433 were
received in a timely manner by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Amendments and Supplements to the Prospectus and Other Securities Act Matters</U>.
If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, not misleading, or if in the opinion of the Agent or counsel for the Agent it is otherwise necessary to amend or supplement the
Prospectus to comply with applicable law, including the Securities Act, the Company agrees (subject to Section&nbsp;4(d) and 4(f)) to promptly prepare, file with the Commission and furnish at its own expense to the Agent, amendments or supplements
to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law including the Securities Act. Neither the Agent&#146;s consent to, or delivery of,
any such amendment or supplement shall constitute a waiver of any of the Company&#146;s obligations under Sections 4(d) and 4(f). Notwithstanding the foregoing, the Company shall not be required to file such amendment or supplement if there is no
pending Issuance Notice and the Company believes that it is in its best interests not to file such amendment or supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
<U>Agent</U><U>&#146;</U><U>s Review of Proposed Amendments and Supplements</U>.<I> </I>Prior to amending or supplementing the Registration Statement (including any registration statement filed under Rule&nbsp;462(b) under the Securities Act) or the
Prospectus (excluding any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof,
a copy of each such proposed amendment or supplement, insofar as such proposed amendment or supplement relates to the transactions contemplated hereby, and the Company shall not file or use any such proposed amendment or supplement without the
Agent&#146;s prior consent (not to be unreasonably withheld, conditioned or delayed), and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such
Rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Use of Free Writing Prospectus</U>. Neither the Company nor the Agent has prepared, used, referred to or distributed, or
will prepare, use, refer to or distribute, without the other party&#146;s prior written consent, any &#147;written communication&#148; that constitutes a &#147;free writing prospectus&#148; as such terms are defined in Rule 405 under the Securities
Act with respect to the offering contemplated by this Agreement (any such free writing prospectus being referred to herein as a &#147;<B>Free Writing Prospectus</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Free Writing Prospectuses</U>. The Company shall furnish to the Agent for review, a
reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto to be prepared by or on behalf of, used by, or referred to by the Company and the
Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Agent&#146;s consent (not to be unreasonably withheld, conditioned or delayed). The Company shall furnish to the Agent,
without charge, as many copies of any free writing prospectus prepared by or on behalf of, or used by the Company, as the Agent may reasonably request. If at any time when a prospectus is required by the Securities Act (including, without
limitation, pursuant to Rule&nbsp;173(d)) to be delivered in connection with sales of the Shares (but in any event if at any time through and including the date of this Agreement) there occurred or occurs an event or development as a result of which
any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material
fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company shall promptly amend or supplement such free
writing prospectus to eliminate or correct such conflict or so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances prevailing at such subsequent time, not misleading, as the case may be; <I>provided, however</I>, that prior to amending or supplementing any such free writing prospectus, the
Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus and the Company shall not file, use or refer to
any such amended or supplemented free writing prospectus without the Agent&#146;s consent (not to be unreasonably withheld, conditioned or delayed). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Filing of Agent Free Writing Prospectuses</U>. The Company shall not take any action that would result in the Agent or the Company
being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Agent that the Agent otherwise would not have been required to file thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Copies of Registration Statement and Prospectus</U>. After the date of this Agreement through the last time that a prospectus is
required by the Securities Act (including, without limitation, pursuant to Rule&nbsp;173(d)) to be delivered in connection with sales of the Shares, the Company agrees to furnish the Agent with copies (which may be electronic copies) of the
Registration Statement and each amendment thereto, and with copies of the Prospectus and each amendment or supplement thereto in the form in which it is filed with the Commission pursuant to the Securities Act or Rule&nbsp;424(b) under the
Securities Act, both in such quantities as the Agent may reasonably request from time to time; and, if the delivery of a prospectus is required under the Securities Act or under the blue sky or securities laws of any jurisdiction at any time on or
prior to the applicable Settlement Date for any period set forth in an Issuance Notice in connection with the offering or sale of the Shares and if at such time any event has occurred as a result of which the Prospectus as then amended or
supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus is delivered,
not misleading, or, if for any other reason it is necessary during such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
same period to amend or supplement the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with the Securities Act or the
Exchange Act, to notify the Agent and to request that the Agent suspend offers to sell Shares (and, if so notified, the Agent shall cease such offers as soon as practicable); and if the Company decides to amend or supplement the Registration
Statement or the Prospectus as then amended or supplemented, to advise the Agent promptly by telephone (with confirmation in writing) and to prepare and cause to be filed promptly with the Commission an amendment or supplement to the Registration
Statement or the Prospectus as then amended or supplemented that will correct such statement or omission or effect such compliance; provided, however, that if during such same period the Agent is required to deliver a prospectus in respect of
transactions in the Shares, the Company shall promptly prepare and file with the Commission such an amendment or supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Blue
Sky Compliance</U>. The Company shall cooperate with the Agent and counsel for the Agent to qualify or register the Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial
securities laws of those jurisdictions designated by the Agent, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Shares. The Company shall not
be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation.
The Company will advise the Agent promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for
any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its reasonable best efforts to obtain the withdrawal thereof as soon as practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Earnings Statement</U>. As soon as practicable, the Company will make generally available to its security holders and to the Agent an
earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section&nbsp;11(a) of
the Securities Act and Rule 158 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Listing; Reservation of Shares</U>. (a)&nbsp;The Company will use
commercially reasonable efforts to maintain the listing of the Shares on the Principal Market; and (b)&nbsp;the Company will reserve and keep available at all times, free of preemptive rights, Shares for the purpose of enabling the Company to
satisfy its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Transfer Agent</U>. The Company shall engage and maintain, at its expense, a
registrar and transfer agent for the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Due Diligence</U>. During the term of this Agreement, the Company will reasonably
cooperate with any reasonable due diligence review conducted by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents and senior corporate officers,
during normal business hours and at the Company&#146;s principal offices, as the Agent may reasonably request from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Representations and Warranties</U>. The Company acknowledges that each delivery of an
Issuance Notice and each delivery of Shares on a Settlement Date shall be deemed to be (i)&nbsp;an affirmation to the Agent that the representations and warranties of the Company contained in or made pursuant to this Agreement are true and correct
as of the date of such Issuance Notice or of such Settlement Date, as the case may be, as though made at and as of each such date, except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any
supplements thereto); and (ii)&nbsp;an undertaking that the Company will advise the Agent if any of such representations and warranties will not be true and correct as of the Settlement Date for the Shares relating to such Issuance Notice, as though
made at and as of each such date (except that such representations and warranties shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented relating to such Shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Deliverables at Triggering Event Dates; Certificates.</U> The Company agrees that on or prior to the date of the first Issuance Notice
and, during the term of this Agreement after the date of the first Issuance Notice, upon: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(A) the filing of the Prospectus or the
amendment or supplement of any Registration Statement or Prospectus (other than a prospectus supplement relating solely to an offering of securities other than the Shares or a prospectus filed pursuant to Section&nbsp;4(a)(ii)(B)), by means of a
post-effective amendment, sticker or supplement, but not by means of incorporation of documents by reference into the Registration Statement or Prospectus; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(B) the filing with the Commission of an annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or a quarterly report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> (including any Form <FONT STYLE="white-space:nowrap">10-K/A</FONT> or Form <FONT STYLE="white-space:nowrap">10-Q/A</FONT> containing amended financial information or a material amendment to the previously filed
annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q),</FONT> in each case, of the Company; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(C) the filing with the Commission of a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of the Company containing amended
financial information (other than information &#147;furnished&#148; pursuant to Item 2.02 or 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> or to provide disclosure pursuant to Item 8.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT>
relating to reclassification of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No.&nbsp;144) that is material to the offering of securities of the Company in the Agent&#146;s reasonable
discretion; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(any such event, a &#147;<B>Triggering Event Date</B>&#148;), the Company shall furnish the Agent (but in the case of clause (C)&nbsp;above
only if the Agent reasonably determines that the information contained in such current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of the Company is material) with a certificate as of the Triggering Event Date, in the form and
substance satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as amended or supplemented,
(A)&nbsp;confirming that the representations and warranties of the Company contained in this Agreement are true and correct, (B)&nbsp;confirming that the Company has performed all of its obligations hereunder to be performed on or prior to the date
of such certificate and as to the matters set forth in <U>Section</U><U></U><U>&nbsp;5(a)(i)</U> hereof, and (C)&nbsp;containing any other certification that the Agent shall reasonably request. The requirement to provide a certificate under this
<U>Section</U><U></U><U>&nbsp;4(o)</U> shall be waived for any Triggering Event Date occurring at a time when no Issuance Notice is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pending or a suspension is in effect, which waiver shall continue until the earlier to occur of the date the Company delivers instructions for the sale of Shares hereunder (which for such
calendar quarter shall be considered a Triggering Event Date) and the next occurring Triggering Event Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Triggering Event Date when a suspension was in
effect and did not provide the Agent with a certificate under this Section&nbsp;4(o), then before the Company delivers the instructions for the sale of Shares or the Agent sells any Shares pursuant to such instructions, the Company shall provide the
Agent with a certificate in conformity with this Section&nbsp;4(o) dated as of the date that the instructions for the sale of Shares are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Legal Opinions.</U> On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to
which the Company is obligated to deliver a certificate pursuant to Section&nbsp;4(o) for which no waiver is applicable and excluding the date of this Agreement, a negative assurances letter and the written legal opinion of Gunderson Dettmer Stough
Villeneuve Franklin&nbsp;&amp; Hachigian, LLP, counsel to the Company, and Dechert LLP, intellectual property counsel to the Company, each dated the date of delivery, in form and substance reasonably satisfactory to Agent and its counsel,
substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented; provided, however, the Company shall be required
to furnish no more than one opinion and negative assurances letter hereunder per calendar quarter. In lieu of such opinions for subsequent periodic filings, in the discretion of the Agent, the Company may furnish a reliance letter from such counsel
to the Agent, permitting the Agent to rely on a previously delivered opinion letter, modified as appropriate for any passage of time or Triggering Event Date (except that statements in such prior opinion shall be deemed to relate to the Registration
Statement and the Prospectus as amended or supplemented as of such Triggering Event Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Comfort Letter</U>. On or prior to the
date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to Section&nbsp;4(o) for which no waiver is applicable and excluding the date of this
Agreement, the Company shall cause the Auditor who has audited the financial statements included or incorporated by reference in the Registration Statement, to furnish the Agent a comfort letter, dated the date of delivery, in form and substance
reasonably satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel; provided, however, that any such comfort letter will only be required on the Triggering Event Date specified to
the extent that it contains financial statements filed with the Commission under the Exchange Act and incorporated or deemed to be incorporated by reference into a Prospectus. If requested by the Agent, the Company shall also cause a comfort letter
to be furnished to the Agent following the date of occurrence of any material transaction or event, while an Issuance Notice is pending or in effect, requiring the filing of a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT>
containing material amended financial information of the Company, including the restatement of the Company&#146;s financial statements and the Agent shall be entitled upon notice to the Company to suspend sales under the pending or effective
Issuance Notice until such comfort letter is furnished to the Agent. The Company shall be required to furnish no more than one comfort letter hereunder per each filing of an annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or a
quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Secretary</U><U>&#146;</U><U>s Certificate</U>. On or prior to the date of the first
Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to Section&nbsp;4(o) for which no waiver is applicable and excluding the date of this Agreement, the
Company shall furnish the Agent a certificate executed by the Secretary of the Company, signing in such capacity, dated the date of delivery (i)&nbsp;certifying that attached thereto are true and complete copies of the resolutions duly adopted by
the Board of Directors of the Company authorizing the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (including, without limitation, the issuance of the Shares pursuant to this Agreement), which
authorization shall be in full force and effect on and as of the date of such certificate, (ii)&nbsp;certifying and attesting to the office, incumbency, due authority and specimen signatures of each Person who executed this Agreement for or on
behalf of the Company, and (iii)&nbsp;containing any other certification that the Agent shall reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U>Agent&#146;s Own
Account; Clients&#146; Account</U>. The Company consents to the Agent trading, in compliance with applicable law, in the Common Shares for the Agent&#146;s own account and for the account of its clients at the same time as sales of the Shares occur
pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Investment Limitation</U>. The Company shall not invest, or otherwise use the proceeds received by the
Company from its sale of the Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Market Activities</U>. The Company will not take, directly or indirectly, any action designed to or that might be reasonably expected
to cause or result in stabilization or manipulation of the price of the Shares or any other reference security, whether to facilitate the sale or resale of the Shares or otherwise, and the Company will, and shall use commercially reasonable efforts
to cause each of its Affiliates to, comply with all applicable provisions of Regulation M. If the limitations of Rule 102 of Regulation M (&#147;<B>Rule 102</B>&#148;) do not apply with respect to the Shares or any other reference security pursuant
to any exception set forth in Section (d)&nbsp;of Rule 102, then promptly upon notice from the Agent (or, if later, at the time stated in the notice), the Company will, and shall use commercially reasonable efforts to cause each of its Affiliates
to, comply with Rule 102 as though such exception were not available but the other provisions of Rule 102 (as interpreted by the Commission) did apply. The Company shall promptly notify the Agent if it no longer meets the requirements set forth in
Section (d)&nbsp;of Rule 102. <B></B><B></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Notice of Other Sale</U>. Without the written consent of the Agent, the Company will
not, directly or indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares or securities convertible into or exchangeable for Common Shares (other than Shares hereunder), warrants or any
rights to purchase or acquire Common Shares, or effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Common Shares, during the period beginning on the third Trading
Day immediately prior to the date on which any Issuance Notice is delivered to the Agent hereunder and ending on the third Trading Day immediately following the Settlement Date with respect to Shares sold pursuant to such Issuance Notice; and will
not directly or indirectly enter into any other &#147;at the market&#148; or continuous equity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares (other than the Shares offered pursuant to this Agreement) or securities
convertible into or exchangeable for Common Shares, warrants or any rights to purchase or acquire, Common Shares prior to the termination of this Agreement; provided, however, that such restrictions will not be required in connection with the
Company&#146;s (i)&nbsp;issuance or sale of Common Shares, options to purchase Common Shares or Common Shares issuable upon the exercise of options or other equity awards pursuant to any employee or director share option, incentive or benefit plan,
share purchase or ownership plan, long-term incentive plan, dividend reinvestment plan, inducement award under the Principal Market rules or other compensation plan of the Company or its subsidiaries, as in effect on the date of this Agreement,
(ii)&nbsp;issuance or sale of Common Shares issuable upon exchange, conversion or redemption of securities or the exercise or vesting of warrants, options or other equity awards outstanding at the date of this Agreement, (iii)&nbsp;issuance or sale
of Common Shares or securities convertible into or exchangeable for Common Shares as consideration for mergers, acquisitions, other similar business combinations, joint ventures or strategic alliances and other business transactions (including,
without limitation, collaborations or arrangement involving research and/or development activities) occurring after the date of this Agreement which are not used for capital raising purposes and (iv)&nbsp;modification of any outstanding options,
warrants of any rights to purchase or acquire Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5. CONDITIONS TO DELIVERY OF ISSUANCE NOTICES AND TO SETTLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Conditions Precedent to the Right of the Company to Deliver an Issuance Notice and the Obligation of the Agent to Sell Shares</U>. The
right of the Company to deliver an Issuance Notice hereunder is subject to the satisfaction, on the date of delivery of such Issuance Notice, and the obligation of the Agent to use its commercially reasonable efforts to place Shares during the
applicable period set forth in the Issuance Notice is subject to the satisfaction, on each Trading Day during the applicable period set forth in the Issuance Notice, of each of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Accuracy of the Company&#146;s Representations and Warranties; Performance by the Company</U>. The Company
shall have delivered the certificate required to be delivered pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U> on or before the date on which delivery of such certificate is required pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U>. The Company
shall have performed, satisfied and complied with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to such date, including, but not limited to, the covenants
contained in <U>Section</U><U></U><U>&nbsp;4(p)</U>, <U>Section</U><U></U><U>&nbsp;4(q)</U> and <U>Section</U><U></U><U>&nbsp;4(r)</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have
been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby that prohibits or directly and materially
adversely affects any of the transactions contemplated by this Agreement, and no proceeding shall have been commenced that may have the effect of prohibiting or materially adversely affecting any of the transactions contemplated by this Agreement.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Material Adverse Changes</U>. Except as disclosed in the Registration Statement or Prospectus and the Time
of Sale Information, (a)&nbsp;in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b)&nbsp;there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential
downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#147;nationally recognized statistical rating
organization&#148; as such term is defined for purposes of Section&nbsp;3(a)(62) of the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Suspension of Trading in or Delisting of Common Shares; Other Events</U>. The trading of the Common
Shares (including without limitation the Shares) shall not have been suspended by the Commission, the Principal Market or FINRA and the Common Shares (including without limitation the Shares) shall have been approved for listing or quotation on and
shall not have been delisted from the Principal Market or any of their constituent markets. There shall not have occurred (and be continuing in the case of occurrences under clauses&nbsp;(i) and (ii)&nbsp;below) any of the following:
(i)&nbsp;trading or quotation in any of the Company&#146;s securities shall have been suspended or limited by the Commission or by the Principal Market or trading in securities generally on the Principal Market shall have been suspended or limited,
or minimum or maximum prices shall have been generally established on any of such stock exchanges by the Commission or the FINRA; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal or New York, authorities; or
(iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development
involving a prospective substantial change in United States&#146; or international political, financial or economic conditions, as in the judgment of the Agent is material and adverse and makes it impracticable to market the Shares in the manner and
on the terms described in the Prospectus or to enforce contracts for the sale of securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Documents Required
to be Delivered on each Issuance Notice Date</U>. The Agent&#146;s obligation to use its commercially reasonable efforts to place Shares hereunder shall additionally be conditioned upon the delivery to the Agent on or before the Issuance Notice Date
of a certificate in form and substance reasonably satisfactory to the Agent, executed by the Chief Executive Officer, President or Chief Financial Officer of the Company, to the effect that all conditions to the delivery of such Issuance Notice
shall have been satisfied as at the date of such certificate (which certificate shall not be required if the foregoing representations shall be set forth in the Issuance Notice). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>No Misstatement or Material Omission</U>. Agent shall not have advised the Company that the Registration Statement, the Prospectus or
the Time of Sale Information, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&#146;s reasonable opinion is material, or omits to state a fact that in the Agent&#146;s reasonable opinion is material and
is required to be stated therein or is necessary to make the statements therein not misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Agent Counsel Legal Opinion</U>. Agent shall have received from Cooley LLP, counsel
for Agent, such opinion or opinions, on or before the date on which the delivery of the Company counsel legal opinion is required pursuant to <U>Section</U><U></U><U>&nbsp;4(p)</U>, with respect to such matters as Agent may reasonably require, and
the Company shall have furnished to such counsel such documents as they request for enabling them to pass upon such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.
INDEMNIFICATION AND CONTRIBUTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Indemnification of the Agent</U>. The Company agrees to indemnify and hold harmless the
Agent, its officers and employees, and each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Agent or such officer,
employee or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at
common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or
alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule&nbsp;430B under the Securities Act, or the omission or alleged
omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus
that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, and to reimburse the Agent and each such officer, employee and controlling person for any and all documented expenses
(including the reasonable and documented fees and disbursements of counsel chosen by the Agent) as such expenses are reasonably incurred by the Agent or such officer, employee or controlling person in connection with investigating, defending,
settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided, however, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the
extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the
Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information
described in subsection (b)&nbsp;below. The indemnity agreement set forth in this <U>Section</U><U></U><U>&nbsp;6(a)</U> shall be in addition to any liabilities that the Company may otherwise have. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Indemnification of the Company, its Directors and Officers</U>. The Agent agrees to
indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act against any
loss, claim, damage, liability or expense, as incurred, to which the Company or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation,
or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a
material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has
used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading; but, for each of (i)&nbsp;and (ii) above, only to the extent arising out of or based upon any untrue statement or alleged untrue statement or
omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment
or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information set forth in the ninth paragraph under the caption &#147;Plan of Distribution&#148; in the
Prospectus, and to reimburse the Company and each such director, officer and controlling person for any and all expenses (including the fees and disbursements of one counsel chosen by the Company) as such expenses are reasonably incurred by the
Company or such officer, director or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The indemnity agreement set forth in this
Section&nbsp;6(b) shall be in addition to any liabilities that the Agent or the Company may otherwise have. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Notifications and
Other Indemnification Procedures</U>. Promptly after receipt by an indemnified party under this <U>Section</U><U></U><U>&nbsp;6</U> of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made
against an indemnifying party under this <U>Section</U><U></U><U>&nbsp;6</U>, notify the indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not relieve it from any liability which it
may have to any indemnified party for contribution or otherwise than under the indemnity agreement contained in this <U>Section</U><U></U><U>&nbsp;6</U> or to the extent it is not prejudiced as a proximate result of such failure. In case any such
action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with
all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to
such indemnified party; provided, however, if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions
of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate
counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying
party&#146;s election so to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this <U>Section</U><U></U><U>&nbsp;6</U> for any legal or other
expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood,
however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with
any local counsel) for the indemnified parties shall be selected by the indemnified party (in the case of counsel for the indemnified parties referred to in <U>Sections 6(a)</U> and <U>6(b</U>)<B> </B>above), (ii)&nbsp;the indemnifying party shall
not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized in writing the
employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Settlements</U>. The indemnifying party under this <U>Section</U><U></U><U>&nbsp;6</U> shall not be liable for any settlement of any
proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or
expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as
contemplated by <U>Section</U><U></U><U>&nbsp;6(c)</U> hereof, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than
30&nbsp;days after receipt by such indemnifying party of the aforesaid request; and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No
indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified
party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on
claims that are the subject matter of such action, suit or proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Contribution</U>. If the indemnification provided for in
this <U>Section</U><U></U><U>&nbsp;6</U> is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each
indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate
to reflect the relative benefits received by the Company, on the one hand, and the Agent, on the other hand, from the offering of the Shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to this Agreement; or (ii)&nbsp;if the allocation provided by clause&nbsp;(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the
relative benefits referred to in clause&nbsp;(i) above but also the relative fault of the Company, on the one hand, and the Agent, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages,
liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Agent, on the other hand, in connection with the offering of the Shares pursuant to this
Agreement shall be deemed to be in the same respective proportions as the total gross proceeds from the offering of the Shares (before deducting expenses) received by the Company bear to the total commissions received by the Agent. The relative
fault of the Company, on the one hand, and the Agent, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a
material fact relates to information supplied by the Company, on the one hand, or the Agent, on the other hand, and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be
deemed to include, subject to the limitations set forth in <U>Section</U><U></U><U>&nbsp;6(c)</U>, any reasonable and documented legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any
action or claim. The provisions set forth in <U>Section</U><U></U><U>&nbsp;6(c)</U> with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this <U>Section</U><U></U><U>&nbsp;6(e)</U>;
<I>provided, however,</I> that no additional notice shall be required with respect to any action for which notice has been given under <U>Section</U><U></U><U>&nbsp;6(c)</U> for purposes of indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Agent agree that it would not be just and equitable if contribution pursuant to this
<U>Section</U><U></U><U>&nbsp;6(e)</U> were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in this <U>Section</U><U></U><U>&nbsp;6(e)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this <U>Section</U><U></U><U>&nbsp;6(e)</U>, the Agent shall not be required to contribute any amount in
excess of the agent fees received by the Agent in connection with the offering contemplated hereby. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. For purposes of this <U>Section</U><U></U><U>&nbsp;6(e)</U>, each officer and employee of the Agent and each person, if any, who controls the Agent within the meaning of the
Securities Act or the Exchange Act shall have the same rights to contribution as the Agent, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within
the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.
TERMINATION&nbsp;&amp; SURVIVAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Term</U>. Subject to the provisions of this <U>Section</U><U></U><U>&nbsp;7</U>, the term of
this Agreement shall continue from the date of this Agreement until the end of the Agency Period, unless earlier terminated by the parties to this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination; Survival Following Termination</U>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Either party may terminate this Agreement prior to the end of the Agency Period, by giving written notice as
required by this Agreement, upon one Trading Day&#146;s notice to the other party; provided that, (A)&nbsp;if the Company terminates this Agreement after the Agent confirms to the Company any sale of Shares, the Company shall remain obligated to
comply with <U>Section&nbsp;3(b)(v)</U> with respect to such Shares and (B)<U>&nbsp;Section</U><U></U><U>&nbsp;2</U>, <U>Section</U><U></U><U>&nbsp;3(d)</U>, <U>Section</U><U></U><U>&nbsp;6</U>, <U>Section</U><U></U><U>&nbsp;7</U> and
<U>Section</U><U></U><U>&nbsp;8</U> shall survive termination of this Agreement. If termination shall occur prior to the Settlement Date for any sale of Shares, such sale shall nevertheless settle in accordance with the terms of this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition to the survival provision of <U>Section</U><U></U><U>&nbsp;7(b)(i)</U>, the respective indemnities,
agreements, representations, warranties and other statements of the Company, of its officers and of the Agent set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf
of the Agent or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Shares sold
hereunder and any termination of this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8. MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Press Releases and Disclosure</U>. The Company may issue a press release describing the material terms of the transactions contemplated
hereby as soon as practicable following the date of this Agreement, and may file with the Commission a Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K,</FONT> with this Agreement attached as an exhibit thereto, describing the
material terms of the transactions contemplated hereby, and the Company shall consult with the Agent prior to making such disclosures, and the parties hereto shall use all commercially reasonable efforts, acting in good faith, to agree upon a text
for such disclosures that is reasonably satisfactory to all parties hereto. No party hereto shall issue thereafter any press release or like public statement (including, without limitation, any disclosure required in reports filed with the
Commission pursuant to the Exchange Act) related to this Agreement or any of the transactions contemplated hereby without the prior written approval of the other party hereto, except as may be necessary or appropriate in the reasonable opinion of
the party seeking to make disclosure to comply with the requirements of applicable law or stock exchange rules and except for the disclosure required pursuant to Section&nbsp;4(a) of this Agreement in the Company&#146;s quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> or annual reports on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> If any such press release or like public statement is so required, the party making such disclosure shall consult with the other party
prior to making such disclosure, and the parties shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosure that is reasonably satisfactory to all parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>No Advisory or Fiduciary Relationship</U>.<B> </B>The Company acknowledges and agrees that (i)&nbsp;the transactions contemplated by
this Agreement, including the determination of any fees, are <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transactions between the Company and the Agent, (ii)&nbsp;when acting as a principal under this Agreement, the Agent is
and has been acting solely as a principal is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
party, (iii)&nbsp;the Agent has not assumed nor will assume an advisory or fiduciary responsibility in favor of the Company with respect to the transactions contemplated hereby or the process
leading thereto (irrespective of whether the Agent has advised or is currently advising the Company on other matters) and the Agent does not have any obligation to the Company with respect to the transactions contemplated hereby except the
obligations expressly set forth in this Agreement, (iv)&nbsp;the Agent and its Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (v)&nbsp;the Agent has not provided any
legal, accounting, regulatory or tax advice with respect to the transactions contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Research Analyst Independence</U>. The Company acknowledges that the Agent&#146;s research analysts and research departments are
required to and should be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and as such the Agent&#146;s research analysts may hold views and make statements or investment
recommendations and/or publish research reports with respect to the Company or the offering that differ from the views of their respective investment banking divisions. The Company understands that the Agent is a full service securities firm and as
such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the
transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Notices</U>. All communications hereunder shall be in writing and shall be mailed,
hand delivered, sent via electronic mail (if applicable) or telecopied and confirmed to the parties hereto as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the Agent:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">520 Madison
Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New&nbsp;York, NY 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Facsimile: (646) <FONT STYLE="white-space:nowrap">786-5719</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with
a copy (which shall not constitute notice) to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">55 Hudson Yards </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, NY
10001 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Facsimile: (212) <FONT STYLE="white-space:nowrap">479-6275</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Daniel I. Goldberg, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: dgoldberg@cooley.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If
to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Aldeyra Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">131 Hartwell Avenue, Suite 320 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Lexington, MA 02421 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:
Chief Executive Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: tbrady@aldeyra.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Gunderson Dettmer Stough Villeneuve Franklin&nbsp;&amp; Hachigian, LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">One Marina Park Drive, Suite 900 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Boston, MA 02210 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:
Keith J. Scherer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: kscherer@gunder.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the others in accordance with this
<U>Section</U><U></U><U>&nbsp;8(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Successors</U>. This Agreement will inure to the benefit of and be binding upon the
parties hereto, and to the benefit of the employees, officers and directors and controlling persons referred to in <U>Section</U><U></U><U>&nbsp;6</U>, and in each case their respective successors, and no other person will have any right or
obligation hereunder. The term &#147;successors&#148; shall not include any purchaser of the Shares as such from the Agent merely by reason of such purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Partial Unenforceability</U>. The invalidity or unenforceability of any Article, Section, paragraph or provision of this Agreement
shall not affect the validity or enforceability of any other Article, Section, paragraph or provision hereof. If any Article, Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall
be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Governing
Law Provisions</U>. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of
or based upon this Agreement or the transactions contemplated hereby may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each
case located in the Borough of Manhattan in the City of New York (collectively, the &#147;<B>Specified Courts</B>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the
enforcement of a judgment of any such court, as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail
to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any
suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an
inconvenient forum. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>General Provisions</U>. This Agreement constitutes the entire agreement of the
parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. The Agent and the Company agree that that concurrently with the
execution of this Agreement, their Sales Agreement entered into on March&nbsp;11, 2021, is terminated in accordance with Section&nbsp;7(b) of such Agreement. This Agreement may be executed in two or more counterparts, each one of which shall be an
original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and may be delivered by facsimile transmission or by electronic delivery of a portable document format (PDF) file (including any electronic
signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com). This Agreement may not be amended or modified unless in writing
by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The Article and Section headings herein are for the convenience of the parties
only and shall not affect the construction or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Immediately Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ALDEYRA THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Todd C. Brady</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Todd C. Brady, M.D., Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby confirmed and accepted by the Agent in New York, New York as of the
date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Donald Lynaugh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Donald Lynaugh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ISSUANCE NOTICE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Date] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: [__________] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the Open Market Sale Agreement<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> between Aldeyra Therapeutics, Inc. (the
&#147;<B>Company</B>&#148;) and Jefferies LLC (the &#147;<B>Agent</B>&#148;) dated as of August&nbsp;1, 2024. The Company confirms that all conditions to the delivery of this Issuance Notice are satisfied as of the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date of Delivery of Issuance Notice (determined pursuant to <U>Section</U><U></U><U>&nbsp;3(b)(i)</U>): </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">_______________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Issuance Amount (equal to the total
Sales Price for such Shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$<U>&#8194;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of days in selling period:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First date of selling period:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Last date of selling period:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Settlement Date(s) if other than standard T+1 settlement:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Floor Price Limitation (in no event less than $1.00 without the prior written consent of the Agent, which consent may be
withheld in the Agent&#146;s sole discretion): $ ____ per share </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comments:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notice Parties </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>The Company </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bruce Greenberg </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Todd Brady, Ph.D., M.D. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>The Agent </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Magarro </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Donald Lynaugh </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d814773dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g814773snap1.jpg" ALT="LOGO" STYLE="width:2.29375in;height:0.572222in;">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">SILICON VALLEY</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">ANN ARBOR</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">AUSTIN</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">BEIJING</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">BOSTON</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">LOS ANGELES</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">NEW YORK</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">SAN DIEGO</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">SAN FRANCISCO</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">S&Atilde;O PAULO</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">SINGAPORE</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">August&nbsp;1, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aldeyra Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">131 Hartwell Avenue, Suite 320 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexington, MA 02421 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Aldeyra Therapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and you have requested our opinion with
respect to certain matters in connection with the offering by the Company of the number of authorized but unissued shares having aggregate sale proceeds of up to $75&nbsp;million (the &#147;<B><I>Shares</I></B>&#148;) of the Company&#146;s common
stock, par value $0.001 (the &#147;<B><I>Common Stock</I></B>&#148;), to be issued pursuant to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-277753)</FONT> (the
&#147;<B><I>Registration Statement</I></B>&#148;) filed on March&nbsp;7, 2024, with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;),
which was declared effective by the Commission on April&nbsp;24, 2024, the related prospectus, included in the Registration Statement (the &#147;<B><I>Base Prospectus</I></B>&#148;), and the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">at-the-market</FONT></FONT> offering prospectus supplement to be filed with the Commission pursuant to Rule 424(b) of the rules and regulations of the Act (the &#147;<B><I>ATM Prospectus Supplement</I></B>&#148;). The Base
Prospectus and the ATM Prospectus Supplement are collectively referred to as the &#147;<B><I>Prospectus</I></B>.&#148; The Shares are to be sold by the Company in accordance with the Open Market Sale Agreement<SUP
STYLE="font-size:75%; vertical-align:top">SM</SUP>, dated August&nbsp;1, 2024 by and between the Company and Jefferies LLC (the &#147;<B><I>Sales Agreement</I></B>&#148;), as described in the ATM Prospectus Supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have examined and relied upon the Registration Statement, the Prospectus, the Company&#146;s Restated Certificate of
Incorporation and Amended and Restated Bylaws, as currently in effect, and the originals or copies certified to our satisfaction of such other documents, records, certificates, memoranda and other instruments as in our judgment are necessary or
appropriate to enable us to render the opinion expressed below. With your consent, we have relied upon certificates and other assurances of officers of the Company as to factual matters without having independently verified such factual matters. We
have assumed the genuineness and authenticity of all documents submitted to us as originals, and the conformity to originals of all documents submitted to us as copies thereof and the due execution and delivery by all parties other than the Company
of all documents where due execution and delivery are a prerequisite to the effectiveness thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is being furnished in connection with the
requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the Prospectus, other than as
expressly stated herein with respect to the issue of the Shares. Our opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. Our opinion herein is expressed solely with
respect to the General Corporation Law of the State of Delaware and we express no opinion with respect to any other laws. Our opinion is based on these laws as in effect on the date hereof, and we disclaim any obligation to advise you of facts,
circumstances, events or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set forth herein, it is our opinion that, when the Shares to
be issued and sold by the Company are issued and paid for in accordance with the terms of the Sales Agreement, such Shares will be validly issued, fully paid and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Legal Matters&#148; in the ATM Prospectus Supplement and to the filing of this opinion as an
exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of the Company. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the
rules and regulations of the Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Gunderson Dettmer Stough Villeneuve Franklin&nbsp;&amp; Hachigian, LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GUNDERSON DETTMER STOUGH VILLENEUVE FRANKLIN&nbsp;&amp; HACHIGIAN, LLP </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g814773g0726220823411.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GDSVF&amp;H\10436456.4 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g814773g0726220822644.jpg" ALT="LOGO">
 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>aldx-20240801.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 8/2/2024 12:08:52 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:aldx="http://aldeyra.com/20240801"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://aldeyra.com/20240801"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aldx-20240801_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aldx-20240801_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>aldx-20240801_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 8/2/2024 12:08:52 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>aldx-20240801_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 8/2/2024 12:08:52 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="aldx-20240801.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g814773g0726220822644.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g814773g0726220822644.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  + S # 2(  A$! Q$!_\0
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''\*4BDC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g814773g0726220823411.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g814773g0726220823411.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I FX# 2(  A$! Q$!_\0
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M-C([CFGOXI2+4]2MYK.:*WL;;SS,XP9.<':OI[T7D&A2L/#=]8>)+"YC\K[
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MGD#KCUQS7=T52;1-CC;KPEJ.ISSWFH2Z=)/,L<3VYB9HBB!L$-D,KY8D$=,
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MTG7OZ5Z#11SL.5&9X=TM]%T"STUVC=K:,1[HU(#8[X-:=%%2,**** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g814773snap1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g814773snap1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MQ&LJ9&#M89'\ZRV-+EB@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * .%^+/_(FC_KY3^1K6E\1$]CPWVKIZG,@H#0.G7BC0+!1[H78>M,#Z
M6\+_ /(I:-_UY0_^@"N&6YUK8S/%'B>YTF[L=*TJR%YK&H;O)C=MJ(HZNY]!
MZ=\&A#-'0'UYK24>($L5NEEPALMWELFT$'YN<YW#\*0%/QWX@NO#'A.YU6SC
MBDGA9 %E!*G+ =B#WII7 K:IXHO+'6_"EE'%"T>KE_.+ Y7"J1MY_P!KOFA(
M#K#TI >9Z-\3+B^'BBWN8;>*]TN&:>T15;;*L8;[W/)! SC'7BJL!WF@WLNI
M^'M-U"=566ZMHYG"?=!902!GMS4VL!@>+]>US3=;T+2="BLGN-3,PS>!]J[%
M5OX3GN>QII 6_"OB.YUDW]EJ-D+/5=.D6.XB5]RG<,JZGT/.*&K +XZU^Z\,
M^$KK5;..*2>)D4+*"5^9PIS@@]Z2 ?H?_"7&\;^W_P"Q_LNP[?L)EW[\C&=W
M&,9_2@#8U"=[73KFXC +Q1,X!Z9 )H \WT[Q]XFBTG2M?UBRTTZ)?2+&[6K.
M)8<G 9@<@C@\#-58#U &I XK4O$'B2^UW4++PQ:Z>\6F;5G>\=@978!MJ!2
M,#C+=Z+ =JM '&:CXBUR_P#$]YH?ABWL3)81JUU<7K/L#-]U%"<YQSGVII6
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MC9#&^%@B_%?Q@MH%%MM@+A -OF;><X[YW?CFCH!=^+7_ "3/5_\ ME_Z.2A
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MX?\ #>G^&K-[:P1OWCF2261MTDC'NQ[T/4"3Q%H5MXET.XTB\>2.WN-NYHB
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MP_\ ] /3O_ 5/\*.9A9!_P (OX?_ .@'IW_@*G^%',PL@_X1?P__ - /3O\
MP%3_  HYF%D)_P (OX?_ .@%IW_@*G^%',PLC3BBC@A2&&-8XT 5448"@= !
JVI#'T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139954289991296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001341235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  01,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ALDEYRA THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-1968197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">131 Hartwell Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lexington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">761-4904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALDX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%
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M?^:+X3]>?P%02P$"% ,4    " !N@0%9!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( &Z! 5F8'=(G
M[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( &Z! 5F97)PC$ 8  )PG   3              "  <P!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ;H$!6:]3I^)O!   .!$
M !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    ( &Z! 5F?H!OPL0(  .(,   -              "  ;(,  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ ;H$!69>*NQS     $P(   L
M         ( !C@\  %]R96QS+RYR96QS4$L! A0#%     @ ;H$!61PX9>H_
M 0  / (   \              ( !=Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( &Z! 5DD'INBK0   /@!   :              "  >,1  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &Z! 5EED'F2&0$
M ,\#   3              "  <@2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     )  D /@(  !(4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d814773d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aldx-20240801.xsd</File>
    <File>aldx-20240801_lab.xml</File>
    <File>aldx-20240801_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d814773d8k.htm">d814773d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d814773d8k.htm": {
   "nsprefix": "aldx",
   "nsuri": "http://aldeyra.com/20240801",
   "dts": {
    "schema": {
     "local": [
      "aldx-20240801.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "aldx-20240801_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aldx-20240801_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d814773d8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-08-01_to_2024-08-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d814773d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-08-01_to_2024-08-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d814773d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://aldeyra.com//20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-24-191518-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-191518-xbrl.zip
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M/R_)UJCK4L]X@4JY7"UA\X#Z+.I.'6L:=X<O;"9HT>03!+M6/BL;,0B^G04
M3&J4?OM\W3?';$(+MNL'U#7CZ<- K 3FO 2M44?;Y[6*T5@#N>X1#YBNZFM
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MF./NE(*:0'PHX8SP0*A/?(^9&#I9Q':)'?@$% O(IEA4>V^LOH+5GX.8H\N
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MAMD=0.&HVEG#(891@_N(^P.39>]8 J>!F9K )9S.IA*ZD4=7+C8#/VP0&,
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MK=23B$GJX+D%6(R@*F<SM,7&( HFE0/OE#T?)P3S#/;]O7RSYT4X^SV9_J&
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MDOOBWP3/=4_4X:S.[$E.GK*A/09C1/ZF\6YP14;7/KX0Q!/@JYP&/7BZ H%
M7%8;&&M5 M<=(NOO(82&E50@$R<YZ-'S# ,G"+>#">'R+:LVNDJRQDD>:=K)
M?9, I*7/-&V0D9;5'PZ:&>8J.GCV)(Z>[#^E=7SR^/&*P,%AP\"S4NBTK9F
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M3QQXG,DD2@G^^DCLC:*LPT'#6H[[8@SC8(CH\OEJ_UH+G%Z29R(>"5B]R[E
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MG7ZIC3BD\Q][9((>]S'2AM&^SHN)B5[C"[+<W;Q(9JG@AJDDBK#F&A,"#$@
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M[,_64M+4*(/FEO*VRJO%13?9:"?6O%=LM#6<>(U;\S(U; 83K*W2R#WWP:
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M@=EFJC;LY*9)*EV</B#K+%/AUZ>DMM9JN2RRN10ZK]:>T!46(:<S2>BUO^4
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MBYHV'TGT.4I^>/ (.S*F&/T!65>:+6UO\>5/^F&^JJ.0R8;=M 0G:K4;HB
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M+6NF)FDR)C8RA&CD4@9IXJP-$&@F/-O8P.$@J%%NY% %P?#\,9C\NRW^\0X
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M>(,1E#1L-GL^I>G"B"Q&2> 3&'U UI(RE1L@)8T WZ$&F_ GH_YHHUDQ$0@
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MD><CPKK9Q T .\#>N-)]J:;XL523>2(P=M$27-BC[36I?&;!$;Z2Z.5RQ-G
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M-ILG,4L\&44)+J(EW(K(-)+"%XM0+#@R+^*.8$'H6T+8$0E( C+KY_-379=
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MPBY2\R6Q%YLB _8BBG@(@A 6"SQ @T%C)11@E/#X'!F/K,!%*#9M/^,HXEN
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M4$L! A0#%     @ ;X$!60EJ=X-Z!@  N48  !4              ( !;0,
M &%L9'@M,C R-# X,#%?;&%B+GAM;%!+ 0(4 Q0    ( &^! 5E5"8FTOP0
M #4L   5              "  1H*  !A;&1X+3(P,C0P.# Q7W!R92YX;6Q0
M2P$"% ,4    " !O@0%9@'WBW(43  #-=   #@              @ $,#P
M9#@Q-#<W,V0X:RYH=&U02P$"% ,4    " !O@0%9]=0[WK:F  #7/0, $
M            @ &](@  9#@Q-#<W,V1E>#$Q+FAT;5!+ 0(4 Q0    ( &^!
M 5GZZT-CT0H  "DD   0              "  :')  !D.#$T-S<S9&5X-3$N
9:'1M4$L%!@     &  8 ?0$  *#4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d814773d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aldx-20240801.xsd" xlink:type="simple"/>
    <context id="duration_2024-08-01_to_2024-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-01</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-259">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-08-01_to_2024-08-01"
      id="Hidden_dei_EntityCentralIndexKey">0001341235</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-270">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-271">2024-08-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-272">ALDEYRA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-273">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-274">001-36332</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-275">20-1968197</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-276">131 Hartwell Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-277">Suite 320</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-278">Lexington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-279">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-280">02421</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-281">(781)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-282">761-4904</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-283">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-284">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-285">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-286">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-287">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-288">ALDX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-289">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-08-01_to_2024-08-01" id="ixv-290">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
